Potential healthcare resource use and associated costs of every 2 month injectable cabotegravir plus rilpivirine long-acting regimen implementation in the Spanish National Healthcare System compared to daily oral HIV treatments

Potential healthcare resource use and associated costs of every 2 month injectable cabotegravir plus rilpivirine long-acting regimen implementation in the Spanish National Healthcare System compared to daily oral HIV treatments | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Research Article Potential healthcare resource use and associated costs of every 2 month injectable cabotegravir plus rilpivirine long-acting regimen implementation in the Spanish National Healthcare System compared to daily oral HIV treatments Laura Amanda Vallejo Aparicio, Victoria Neches García, Beatriz Hernández-Novoa, and 4 more This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-3872460/v1 This work is licensed under a CC BY 4.0 License Status: Published Journal Publication published 02 Aug, 2024 Read the published version in BMC Infectious Diseases → Version 1 posted 12 You are reading this latest preprint version Abstract Introduction: HIV treatment currently consists of daily oral antiretroviral therapy (ART). Cabotegravir + rilpivirine long-acting (CAB + RPV LA) is the first ART available in Spain administered every 2 months through intramuscular injection by a healthcare professional (HCP). The objective of this analysis was to assess potential healthcare resource use (HRU) and cost impact of implementing CAB + RPV LA vs. daily oral ART at National Health System (NHS) hospitals. Methods Online quantitative interviews and cost analysis were performed. Infectious disease specialists (IDS), hospital pharmacists (HP) and nurses were asked about their perception of potential differences in HRU between CAB + RPV LA vs. daily oral ART, among other concepts of interest. Spanish official tariffs were applied as unit costs to the HRU estimates (€2,022). Results 120 responders (n = 40 IDS, n = 40 HP, n = 40 nurses) estimated an average number of annual visits per patient by speciality (IDS, HP, and nurse, respectively) of 3.3 vs. 3.7; 4.4 vs. 6.2; 6.1 vs. 3.9, for CAB + RPV LA vs. daily oral ART, and 3.0 vs. 3.2; 4.8 vs. 5.8; 6.9 vs. 4.9, respectively when adjusting by corresponding specialist responses. Estimation by the total sample led to an annual total cost per patient of €2,076 vs. €2,473, being €2,032 vs. €2,237 after adjusting by corresponding HCP, for CAB + RPV LA vs. daily oral ART. Conclusions These results suggest that the implementation of CAB + RPV LA in NHS hospitals would not incur in increased HRU-related costs compared to current daily oral ARTs, being potentially neutral or even cost-saving. Antiretroviral agents cabotegravir Costs and Cost Analysis healthcare resource use HIV long-acting injectable rilpivirine Figures Figure 1 Figure 2 Figure 3 Figure 4 Why carry out this study? Main clinical guidelines in HIV recommend the use of daily oral antiretroviral combinations. Recently, a long-acting regimen consisting of cabotegravir plus rilpivirine (CAB+RPV LA) gluteal intramuscular injections has become available in Spain for maintaining HIV-1 suppression. Given that the long-acting regimes is administered every 2 months, it is anticipated to have a different patient pathway within the hospital compared to daily oral ART, which may lead to changes in healthcare resources and associated costs needed for HIV treatment. What was learned from the study? The total annual cost per patient ranged from €2,032 to €2,076 for CAB+RPV LA, and from €2,237 to €2,473 for daily oral ART. This figures suggest that the implementation of CAB+RPV LA in Spanish NHS hospitals would not translate into increased healthcare resource utilization-related costs associated to a different patient pathway compared to current daily oral ART, being potentially cost-saving. Introduction The first cases of AIDS were described in 1981, and over four decades later, HIV remains one of the main public health concerns with 38.4 million people currently living with HIV worldwide, 1.7 million of them being children, with 1.5 million newly acquiring HIV every year and almost 700,000 AIDS-related deaths in 2020 [ 1 – 3 ]. In Spain, 151,387 people are estimated to be living with HIV, with an average of over 3,500 new cases diagnosed every year in the last decade, although it has been in decline in the past two years [ 4 – 6 ]. Survival of people with HIV (PHIV) has greatly improved in the last couple of decades thanks to the evolution of antiretroviral therapy (ART), resulting in the chronification of the disease [ 7 ]. Nowadays, PHIV that are diagnosed early and are capable of taking continuous ART have a life expectancy that approaches that of general population, so their care focus currently should not only be on achieving and maintaining viral suppression, but also on managing age-related comorbidities, the use of concomitant treatments, drug-related toxicity and improving quality of life of people living with HIV (PLHIV) [ 8 – 12 ]. In 2014 the Joint United Nations Programme on HIV/AIDS (UNAIDS) established the 90-90-90 target: by 2020, 90% of all people living with HIV know their HIV status, 90% of all people diagnosed with HIV receive sustained antiretroviral therapy, and 90% of all people receiving antiretroviral therapy have viral suppression, aiming to reach 95-95-95 initially by 2030 [ 13 ] and recently accelerated to 2025 [ 14 ]. Also, a ‘fourth 90’ was deemed necessary in terms of quality of life of people with viral load (VL) suppression would have good health-related quality of life, entailing attention to both comorbidities and self-perceived quality of life, resulting in a more people-centred approach from health systems [ 15 ]. Recently this concept has been further evolved by an international multidisciplinary panel of HIV experts agreeing on a consensus statement for the long-term wellbeing of PHIV [ 16 ]. Until recently, all ART regimens recommended by the main clinical guidelines were based on daily oral antiretroviral combinations [ 17 – 19 ]. Cabotegravir plus rilpivirine (CAB + RPV) gluteal intramuscular injections administered by a healthcare professional (HCP) is the first and only long acting (LA) regimen available for maintaining HIV-1 suppression. This innovative LA ART authorized in Europe in December 2020 for the treatment of HIV-1 infection in adults who are virologically suppressed, became recently available also in Spain [ 20 – 25 ]. This new regimen transforms the treatment paradigm of PHIV, as it is dosed less frequently than daily oral ART, is subject to fewer drug interactions, and may be beneficial or improve the quality of life for individuals with pill fatigue or concerns about disclosure of their HIV status or stigma associated with intake of daily oral medication [ 20 , 21 , 23 , 24 , 26 ]. CAB + RPV LA was evaluated in three phase III randomized, active-controlled, non-inferiority clinical trials: FLAIR [ 27 ], ATLAS [ 28 ] and ATLAS-2M [ 29 ]. The ATLAS and FLAIR trials demonstrated the non-inferiority of CAB + RPV LA at 48 weeks dosed Q4W (monthly) versus daily oral ART (any triple ART for ATLAS or Triumeq® for FLAIR) in both individual trial analysis [adjusted difference in proportion of patients with VL > 50 copies/ml: ATLAS: 0.6% (95% CI: −1.2 to 2.5); FLAIR: 0.4% (95% CI: −2.8 to 2.1)] as in the pooled analysis of both [adjusted difference in the proportion of patients with VL > 50 copies/mL: 0.2% (CI 95%: −1.4 to 1.7)]. Subsequently, the phase IIIb ATLAS-2M trial demonstrated at 48 weeks the non-inferiority of CAB + RPV LA Q8W (every 2 months) versus Q4W dosing [adjusted difference in the proportion of patients with VL > 50 copies/mL: 0.8% (95% CI: −0.6 to 2.2)]. CAB + RPV LA dosed Q4W or Q8W maintained virologic suppression (HIV RNA < 50 c/mL) at 48 weeks in 94% (n = 1,531/1,636) of the participants in the three phase III/IIIb trials. The safety profile of CAB + RPV LA in the ATLAS and FLAIR trials was comparable to that of current oral ART. Injection Site Reactions (ISRs) occurred in 25% of injections, the majority (98%) were mild/moderate in grade, lasting a median of 3 days, and the number of discontinuations for ISRs was very low (< 2% of patients). 97–99% of the participants in the phase III/IIIb clinical trials preferred CAB + RPV LA vs daily oral ART supporting the patient preference for a long-acting treatment [ 30 , 31 ]. Considering frequency of administration every 2 months vs current recommended daily oral ART regimens for virologically suppressed PHIV, the new long-acting CAB + RPV injectable regimen is anticipated to have a different patient pathway within the Spanish National Health System (NHS) hospitals when implemented, compared to daily oral ART [ 32 – 34 ], which may lead to changes in the healthcare resources and its associated costs needed for its administration. The objective of this study was to evaluate the potential differences in healthcare resource use and its impact on associated costs resulting from the implementation of CAB + RPV LA compared to current daily oral ART from the perspective of Spanish NHS hospitals. Methods We performed a cross-sectional study consisting of online quantitative interviews (CAWI, Computer Assisted Web Interviewing) of HCPs involved in hospital HIV treatment and daily care: infectious disease specialists, hospital pharmacists, and nurses, followed by a cost analysis based on the results obtained. HCPs were recruited by phone and then completed the online questionnaire not exceeding 25 minutes in length. In the CAWI, after presenting, HCPs were asked about their perception of the potential differences in the healthcare resource utilization (HRU) between oral ART and CAB + RPV LA; precisely, estimations on the annual number of visits per patient required to the infectious disease specialist, to the hospital pharmacy and to the nursing team were collected. The interviews were carried out between May 19th and June 3rd, 2022. Although the focus was HRU and its associated costs, to fully understand how the implementation of the new injectable regimen was perceived by the HCPs, other concepts were asked in the CAWI, such as the general assessment of CAB + RPV LA, potential administration management and logistics of CAB + RPV LA, staff and capacity of the hospital, and training or information needs from the patient. All interviews were conducted considering the current regulation on the protection of personal data and pharmacovigilance. Given that answers were based on estimations/opinions and no patient-related information was included, there was no need for an approval from an Ethics Committee. HCPs involved received economic compensation for their participation in the project. Responses to the interviews were collected in a database and analysed with Gandia BarbWin and Microsoft Excel. Qualitative answers were assessed as the frequency of occurrence over the total number of answers for the question, and quantitative answers as averages and their 95% confidence interval (95% CI). Regarding HRU, HCPs were asked about their estimation on the number of times that a virologically suppressed PHIV on treatment with ART or with CAB + RPV LA would visit the infectious disease specialist office, the hospital pharmacy, and the nursing team, in a 12-month period. At the time of the survey, CAB + RPV LA was not yet commercialized in Spain, but several HCPs have had previous experience from clinical trials. Questions about visits to hospital pharmacy and nursing team were disaggregated by therapeutic objective (routine control and follow-up, specific adherence check-ins, patient counselling…). Assuming that more than one therapeutic objective can be covered in each visit, the maximum number of visits estimated by each specialist for both nursing and hospital pharmacy was obtained. The questionnaire used in the CAWI is available as Supplementary Material. From the information obtained on HRU estimates in the CAWI, unit costs from official tariffs published by the Autonomous Regions of Spain, updated to € 2,022 through Spanish Consumer Price Index data [ 35 ], were used to perform the cost analysis. The unitary cost of each resource was multiplied by the frequency of use of each resource estimated by each interviewee (individual data) for each regimen, according to the following formula: $$Total costs={HRU}_{1}*{unit cost}_{1}+{HRU}_{2}*{unit cost}_{2}+\dots +{HRU}_{n}*{unit cost}_{n}$$ where HRU represents the estimated frequency a given healthcare resource has been used by each regimen, and unit cost the cost associated to each use of a given resource by each regimen. Subsequently, the average cost was calculated based on two methodologies: HRU from the visits estimated by the whole sample of respondents (i.e., estimated number of visits to the infectious disease specialist based on answers from infectious disease specialists, hospital pharmacists, and nurses), and HRU estimated by the corresponding specialist (i.e., estimated number of visits to the infectious disease specialist based solely on answers received specifically from infectious disease specialists). Results A total of 120 HCPs were interviewed: 40 Infectious disease specialists, 40 hospital pharmacists, and 40 nurses, with a mean (standard deviation) of 194 (174) PHIV seen monthly and 19.9 (8.3) years of experience with injectable treatments. A summary of the key characteristics of the sample interviewed is shown in Table 1 . Table 1 Characteristics of the sample interviewed Infectious disease specialist (n = 40) Hospital pharmacist (n = 40) Nurse (n = 40) Total (n = 120) HIV patients seen monthly , mean (SD) 142 (74) 321 (218) 117 (117) 194 (174) Years of experience with injectable treatments , mean (SD) 21.3 (7.8) 19.3 (6.8) 19.2 (10.1) 19.9 (8.3) Autonomous region , n (%) Andalucía 2 (5%) 6 (15%) 5 (13%) 13 (11%) Aragón 1 (3%) 0 (0%) 0 (0%) 1 (1%) Principado de Asturias 1 (3%) 0 (0%) 1 (3%) 2 (2%) Islas Baleares 0 (0%) 2 (5%) 0 (0%) 2 (2%) Canarias 0 (0%) 2 (5%) 1 (3%) 3 (3%) Cantabria 1 (3%) 1 (3%) 1 (3%) 3 (3%) Castilla - La Mancha 3 (8%) 2 (5%) 0 (0%) 5 (4%) Castilla y León 1 (3%) 1 (3%) 0 (0%) 2 (2%) Cataluña 9 (23%) 9 (23%) 8 (20%) 26 (22%) Comunidad Valenciana 5 (13%) 5 (13%) 6 (15%) 16 (13%) Extremadura 1 (3%) 0 (0%) 0 (0%) 1 (1%) Galicia 3 (8%) 2 (5%) 1 (3%) 6 (5%) Comunidad de Madrid 13 (33%) 8 (20%) 14 (35%) 35 (29%) Región de Murcia 0 (0%) 0 (0%) 3 (8%) 3 (3%) Comunidad Foral de Navarra 0 (0%) 1 (3%) 0 (0%) 1 (1%) País Vasco 0 (0%) 1 (3%) 0 (0%) 1 (1%) Hospital size , n (%) Large (> 500 beds) 24 (60%) 30 (75%) 27 (68%) 81 (68%) Medium (≥ 200 & ≤500 beds) 16 (40%) 10 (25%) 13 (33%) 39 (33%) Small (< 200 beds) 0 (0%) 0 (0%) 0 (0%) 0 (0%) N, sample included; SD, standard deviation. Regarding the general assessment of CAB + RPV LA, this new injectable regimen scored an 8.7 in an increasing scale from 1 to 10 measuring the level of interest among HCPs, with 71% of the specialists being aware of its clinical development. Fatigue associated with daily oral ART were mentioned by 61% of the HCPs as the profile that could benefit the most from CAB + RPV LA, followed by suboptimal adherence to oral ART (59%) and emotional difficulties associated with oral ART (56%). The main drivers identified for the implementation of CAB + RPV LA were the improvement of therapeutic compliance (73%), decreased stigma associated with oral ART (72%) and greater logistical flexibility (68%). As for the barriers of implementing CAB + RPV LA, 72% of the specialists mentioned the injection procedure, 59% the extra workload for the nursing team and 56% the need for the PHIV to visit the hospital every 2 months. Finally, up to 74% of the HCPs considered that CAB + RPV LA would improve the people’s quality of life compared to oral ART (score: 8.1 out of 10). In general, 66% of the HCPs declared not having any concern regarding the implementation of CAB + RPV LA, and those who did (34%), mentioned the work overload of the nursing team (22%) and the economic cost (22%) as their main worries. As to the implications on staff and capacity of the hospital, 41% of the HCPs indicated that new resources would be needed in the hospital for the administration of CAB + RPV LA, mostly through increasing the nursing staff (63%). Regarding materials to be shared with PHIV, 88% of the HCPs demanded information about adverse events and 79% information about injection site reactions and importance of maintaining an optimum adherence, being applications (71%), printed materials (70%) and websites (54%) the preferred platforms with which to share the information. Finally, in terms of HRU, the estimated average (95% CI) annual visits per patient reported by the total sample of HCPs for CAB + RPV LA vs. daily oral ART respectively were 3.3 (95% CI: 2.8 to 3.7) vs. 3.7 (95% CI: 3.1 to 4.3) for visits to infectious disease specialist; 4.4 (95% CI: 4.0 to 4.8) vs. 6.2 (95% CI: 5.8 to 6.7) to the hospital pharmacy; and 6.1 (95% CI: 5.4 to 6.8) vs. 3.9 (95% CI: 3.4 to 4.3) to the nursing team (Fig. 1 ). When considering the results as reported by the corresponding specialist, the estimated average (95% CI) annual visits per patient for CAB + RPV LA vs. daily oral ART respectively were 3.0 (95% CI: 2.5 to 3.4) vs. 3.2 (95% CI: 2.6 to 3.7); 4.8 (95% CI: 4.2 to 5.4) vs. 5.8 (95% CI: 5.3 to 6.3); and 6.9 (95% CI: 4.8 to 9.0) vs. 4.9 (95% CI: 3.9 to 5.9) (Fig. 2 ). Regarding visits to infectious disease specialists’ little to no differences were expected by HCPs, not being statistically significant. A shift from hospital pharmacy to nursing team visits, with CAB + RPV LA compared to daily oral ART, within the hospital was observed. Differences in annual visits per patient to hospital pharmacy and nursing team between regimens were statistically significant at a 95% confidence level on both methodologies. Unit costs for each resource, updated to 2022, are shown in Table 2 . When applying the unit costs to each HRU, the estimation by total sample of HCPs led to a total annual cost per patient (95% CI) of 2,076 € (95% CI: 1,887 € to 2,265 €) vs. 2,473 € (95% CI: 2,202 € to 2,745 €) for CAB + RPV LA vs. daily oral ART, being 2,032 € (95% CI: 1,966 € to 2,099 €) vs. 2,237 € (95% CI: 2,162 € to 2,312 €), respectively, after adjusting by the corresponding specialist. Differences in total annual costs per patient between regimens were statistically significant at a 95% confidence level on both methodologies. Detailed results from the cost analysis for each methodology are shown in and Fig. 3 and Fig. 4 . Table 2 Unit costs of the healthcare resources Concept Unit cost (€ 2022) Source Visits to the infectious disease specialist 370.42 € Servicio de Salud (2017). Diario Oficial de Castilla-La Mancha núm. 226 [ 42 ] Visits to the hospital pharmacy 165.00 € Osakidetza-Servicio Vasco de Salud (2021). Boletín Oficial del País Vasco, número 3 [ 43 ] Visits to the nursing team 22.00 € Osakidetza-Servicio Vasco de Salud (2021). Boletín Oficial del País Vasco, número 3 [ 43 ] Despite the expected shift in the number of visits from hospital pharmacists to nursing teams, when translated to costs, CAB + RPV LA did not incur in increased HRU-related total costs due to its implementation within the hospital’s PHIV pathways compared to daily oral ART regimes, even being potentially cost-saving. Discussion CAB + RPV LA is the first and only innovative ART regimen administered every 2 months through HCP-administered intramuscular injections that has shown to be non-inferior to current daily oral ART options [ 27 – 29 , 36 ]. Being a new paradigm in HIV treatment and an HCP-administered injectable regimen, the implementation of CAB + RPV LA may result in a different patient pathway for PHIV within NHS hospitals [ 23 , 26 ]. Overall, HCPs anticipated that the implementation of CAB + RPV LA may transfer hospital pharmacy visits to nursing team visits, compared to current practices with daily oral ART. The costs analysis showed that these changes in the patient pathway for CAB + RPV LA administration with regards of the number of visits could lead to savings of approximately 200–400 € per patient per year compared to daily oral ART, due to the reduction in visits to the hospital pharmacist, that would outweigh the increase in visits to the nursing team. These results highlight that the implementation of CAB + RPV LA in the NHS hospitals may not incur in increased HRU-related costs. In the present study, the main barriers detected by HCPs for implementing CAB + RPV LA were the injection procedure, the extra workload for the nursing team and the need to visit the hospital every 2 months. These results are very similar to the findings from the CARISEL study, a phase IIIb hybrid implementation-effectiveness trial that examined the acceptability, appropriateness and feasibility of CAB + RPV LA in Europe, where the increased number of visits, increase in staff workload and potential discomfort of injection were identified as the main barriers by staff HCPs at baseline [ 37 , 38 ]. However, at month 5, as staff gained experience, there was an average decrease of 43% in the proportion of staff HCPs reporting these barriers [ 37 , 38 ]. Also, visiting the hospital every 2 months, identified as a barrier by the HCPs in our study, was considered acceptable by almost 98% of the CARISEL patient study participants [ 39 ]. Staffing and workload concerns were among the most mentioned issues in the interviews, both for the CAB + RPV LA regimen itself and its implementation. Results from CARISEL study showed that mean appointment duration was reduced by 30.4% between month 1 and month 6, meaning that healthcare professionals have a steep learning curve and the initial increase in workload is quickly adjusted [ 39 ]. In a prior study, a multidisciplinary expert panel composed by the main agents involved in PHIV healthcare (the three profiles involved in the current study plus healthcare evaluators and patient association representatives) assessed the added value contribution of CAB + RPV LA to management of HIV in Spain compared to daily oral single-tablet regimens using a MCDA (Multi-Criteria Decision Analysis) methodology [ 40 ]. Findings were in line with those reported in the present study, as therapeutic benefit of CAB + RPV LA was highly valued, as the potential benefit in adherence and stigma-related issues may improve overall quality of life for PHIV [ 40 ]. The potential implementation of CAB + RPV LA was also perceived as positive, and most of the clinical experts considered that the NHS hospitals are prepared for the correct use and implementation of CAB + RPV LA [ 40 ]. This study has some limitations. First, as CAB + RPV LA was not yet commercially available in Spain at the time of the study, the results rely on previous experience in clinical trials and perceptions of the HCPs included. However, this could only be further addressed in the future with real-world evidence studies regarding CAB + RPV LA implementation. Also, the hospitals included in the analysis are only a sample and might not be representative of the whole universe of hospitals in the Spanish NHS. The final sample of HCPs might also be unbalanced in terms of the representativeness of HCPs across all regions in Spain. It is also worth noting that most of the HCPs worked in large hospitals (> 500 beds), representing about 66% of the total amount of large hospitals in Spain, while only 17% of the medium (≥ 200 - ≤500 beds), and 0% of the small (< 200 beds) hospitals were included [ 41 ]. Regarding the cost analysis, only visits to infectious disease specialist, hospital pharmacy and nursing team were considered which could be a simplification of the total healthcare resources needed for each treatment pathway for a long-acting injectable vs daily oral ART; however, these were highlighted as the most important resources in terms of human resources. Finally, unitary costs were retrieved from official tariffs published by two Autonomous Regions of Spain, which may not be representative at the national level, but in the absence of National data this was the best approach as done in prior economic studies published in Spain. To the best of our knowledge, this is the first study evaluating the potential economic impact of implementing CAB + RPV LA vs daily oral ART for the treatment PHIV in Spain using a representative sample of relevant HCPs. Results from this study suggest that the implementation of CAB + RPV LA in Spanish NHS hospitals would not incur in increased HRU-related costs associated to a different patient pathway compared to current daily oral ART, being potentially neutral or even cost-saving. Future real-world evidence studies would complement our results. Declarations Acknowledgments The authors would like to thank the healthcare professionals involved in the interviews for their willingness to participate and their input. All authors contributed to the study conception and design. Material preparation, data collection and analysis were performed by all authors. The first draft of the manuscript was written by all authors and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript. Funding This work was funded by ViiV Healthcare. Conflict of interests Laura-Amanda Vallejo Aparicio is employee and holds stocks of GSK group of companies; Victoria Neches García is employee of GSK group of companies; Beatriz Hernández-Novoa is employee and holds stocks of ViiV Healthcare; Gregorio Casado, Ferrán Jodar, Marco Pinel and Daniel Callejo Velasco are employees of IQVIA. IQVIA received fees from ViiV Healthcare for conducting the study. Ethics All interviews were conducted considering the current regulation on the protection of personal data and pharmacovigilance and in accordance to the EPHMRA Code of Conduct 2022. Given that this study met all requirements to be considered a market research study, according to the EPHMRA Code of Conduct 2022 it did not require Clinical Research Ethics Committee or Independent Review Board approval. HCPs involved received economic compensation for their participation in the project. Data Availability The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request. References Global Report. UNAIDS report on the global AIDS epidemic 2021. Available at: https://www.unaids.org/sites/default/files/media_asset/UNAIDS_FactSheet_en.pdf . United Nations. World Leaders in General Assembly Adopt Political Declaration Pledging Urgent, Transformative Action to Stop Global AIDS Epidemic by 2030 [press release]. Available at: https://press.un.org/en/2021/ga12333.doc.htm . Centers for Disease Control (CDC). Pneumocystis pneumonia–Los Angeles. MMWR Morb Mortal Wkly Rep. 1981;30(21):250–2. Ministerio de Sanidad. Vigilancia epidemiológica del VIH y SIDA en España 2020. Actualización 30 de junio de 2021. November 2021. Available at: https://www.sanidad.gob.es/ciudadanos/enfLesiones/enfTransmisibles/sida/vigilancia/Informe_VIH_SIDA_WEB.pdf . Unidad de vigilancia del VIH, ITS y hepatitis. Actualización del Continuo de Atención del VIH en España, 2017–2019. Madrid: Centro Nacional de Epidemiología – Instituto de Salud Carlos III / Plan Nacional sobre el Sida – Dirección General de Salud Pública. 2020. Disponible en: https://www.sanidad.gob.es/ciudadanos/enfLesiones/enfTransmisibles/sida/vigilancia/ESTIMACION_DEL_CONTINUO_DE_ATENCIoN_DEL_VIH_EN_ESPAnA_Nov2020.pdf [Acceso: febrero 2023]. DIRECCIÓN GENERAL DE SALUD PÚBLICA. VIGILANCIA EPIDEMIOLÓGICA DEL, VIH y SIDA, EN ESPAÑA. 2021 https://www.isciii.es/QueHacemos/Servicios/VigilanciaSaludPublicaRENAVE/EnfermedadesTransmisibles/Documents/VIH/informes%20de%20vigilancia%20VIH%20y%20sida%20anteriores/Informe%20VIH_SIDA_2022_CCAA.pdf . Gueler A, Moser A, Calmy A, Günthard HF, Bernasconi E, Furrer H, et al. Life expectancy in HIV-positive persons in Switzerland: matched comparison with general population. Aids. 2017;31(3):427–36. 10.1097/qad.0000000000001335 . Epub 2016/11/11. Wandeler G, Johnson LF, Egger M. Trends in life expectancy of HIV-positive adults on antiretroviral therapy across the globe: comparisons with general population. Curr Opin HIV AIDS. 2016;11(5):492–500. 10.1097/coh.0000000000000298 . Epub 2016/06/03. Schouten J, Wit FW, Stolte IG, Kootstra NA, van der Valk M, Geerlings SE, et al. Cross-sectional comparison of the prevalence of age-associated comorbidities and their risk factors between HIV-infected and uninfected individuals: the AGEhIV cohort study. Clin Infect Dis. 2014;59(12):1787–97. 10.1093/cid/ciu701 . Epub 2014/09/04. Althoff KN, Smit M, Reiss P, Justice AC. HIV and ageing: improving quantity and quality of life. Curr Opin HIV AIDS. 2016;11(5):527–36. 10.1097/coh.0000000000000305 . Epub 2016/07/02. Gimeno-Gracia M, Sánchez-Rubio-Ferrández J, Robustillo-Cortés MLA, Morillo-Verdugo R. Prevalence of polypharmacy and pharmacotherapy complexity in elderly people living with HIV in Spain. POINT study. Farm Hosp. 2020;44(4):127–34. 10.7399/fh.11367 . Epub 2020/07/11. Collaboration Antiretroviral Therapy Cohort. Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies. Lancet HIV. 2017;4:e349–56. Joint United Nations Programme on HIV/AIDS (UNAIDS). Fast-Track: ending the AIDS epidemic by 2030. 2014. Joint United Nations Programme on HIV/AIDS (UNAIDS). 2025 AIDS TARGETS. Available at: https://aidstargets2025.unaids.org/# [Accessed: march 2023]. 2014. Lazarus JV, Safreed-Harmon K, Barton SE, Costagliola D, Dedes N, del Amo Valero J, et al. Beyond viral suppression of HIV – the new quality of life frontier. BMC Med. 2016;14(1):94. 10.1186/s12916-016-0640-4 . Consensus statement on the role of health systems in advancing the long-term well-being of people living with HIV. NATURE COMMUNICATIONS. (2021) 12:4450. Available at: https://doi.org/10.1038/s41467-021-24673-w . Panel de expertos de GeSIDA y División de control de VIH, ITS, Hepatitis virales y Tuberculosis. Plan Nacional sobre el Sida. (2022) Documento de consenso de GeSIDA/Plan Nacional sobre el SIDA respecto al tratamiento antirretroviral en adultos infectados por el virus de la inmunodeficiencia humana. https://gesida-seimc.org/wp-content/uploads/2022/05/GuiaGeSIDAPlanNacionalSobreElSidaRespectoAlTratamientoAntirretroviralEnAdultosInfectadosPorElVirusDeLaInmunodeficienciaHumanaActualizacionEnero2022.pdf . European AIDS Clinical Society (EACS). (2021) EACS Guidelines version 11.0, October 2021. https://www.eacsociety.org/media/final2021eacsguidelinesv11.0_oct2021.pdf . Gandhi RT, Bedimo R, Hoy JF, Landovitz RJ, Smith DM, Eaton EF, et al. Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2022 Recommendations of the International Antiviral Society–USA Panel. JAMA. 2023;329(1):63–84. 10.1001/jama.2022.22246 . Bares SH, et al. Curr Opin HIV AIDS. 2022;17(1):22–31. Rana AI, et al. Drugs. 2020;80(6):535–45. European Medicines Agency. VOCABRIA Available at: https://www.ema.europa.eu/en/medicines/human/EPAR/vocabria . D'Amico R, Margolis DA. Long-acting injectable therapy: an emerging paradigm for the treatment of HIV infection. Curr Opin HIV AIDS. 2020;15(1):13–8. 10.1097/coh.0000000000000606 . Epub 2019/11/26. DHHS Guidelines for the use of antiretroviral agents in adults and adolescents with HIV, Sept. 2022. Available at: https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/adult-adolescent-arv/guidelines-adult-adolescent-arv.pdf (accessed December 2022). GESIDA Guidelines National Plan on AIDS regarding the antiretroviral treatment in adults infected with HIV. Jan 2022. Available at: https://gesida-seimc.org/wp-content/uploads/2022/03/plan_nacional_gesida_tratamiento_antirretroviral.pdf (accessed December 2022). Thoueille P, Choong E, Cavassini M, Buclin T, Decosterd LA. Long-acting antiretrovirals: a new era for the management and prevention of HIV infection. J Antimicrob Chemother. 2022;77(2):290–302. 10.1093/jac/dkab324 . Epub 2021/09/10. ClinicalTrials.gov. Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants (FLAIR) https://clinicaltrials.gov/ct2/show/NCT02938520 . ClinicalTrials.gov. Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected Adults (ATLAS) https://clinicaltrials.gov/ct2/show/NCT02951052?term=NCT02951052 &draw=2&rank=1. ClinicalTrials.gov. Efficacy, Safety and Tolerability Study of Long-acting Cabotegravir Plus Long-acting Rilpivirine (CAB LA + RPV LA) in Human-immunodeficiency Virus-1 (HIV-1) Infected Adults (ATLAS-2M) https://www.clinicaltrials.gov/ct2/show/NCT03299049 . Overton ET, Richmond G, Rizzardini G, Jaeger H, Orrell C, Nagimova F, et al. Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study. Lancet. 2021;396(10267):1994–2005. 10.1016/s0140-6736(20)32666-0 . Epub 2020/12/15. Murray M, Antela A, Mills A, et al. Patient-reported outcomes in ATLAS and FLAIR participants on long-acting regimens of cabotegravir and ilpivirina over 48 weeks. AIDS Behav. 2020;24:3533–44. Bhattacharya R, Herren K, Poonawalla I, Bunniran S, Bloomfield A, Schwab P. Comparing Medical Utilization and Cost Outcomes in Oral Versus Injectable Immunotherapy Users with Chronic Inflammatory Joint and Skin Diseases. J Manag Care Spec Pharm. 2020;26(10):1246–56. 10.18553/jmcp.2020.26.10.1246 . Epub 2020/10/01. Vidal-Alaball J, Butler CC, Potter CC. Comparing costs of intramuscular and oral vitamin B12 administration in primary care: a cost-minimization analysis. Eur J Gen Pract. 2006;12(4):169–73. Epub 2006/11/28. doi: 10.1080/14017430601049449. PubMed PMID: 17127603. Offord S, Wong B, Mirski D, Baker RA, Lin J. Healthcare resource usage of schizophrenia patients initiating long-acting injectable antipsychotics vs oral. J Med Econ. 2013;16(2):231–9. 10.3111/13696998.2012.751025 . Instituto Nacional de Estadística (INE). Indice de precios de consumo (IPC). Medias anuales. Consultado: junio 2022. Ramgopal et al. CROI 2023; Virtual and Seattle, WA. Oral presentation 191. Gutner C et al. Cabotegravir And Rilpivirine Implementation Study in European Locations (CARISEL): examining healthcare staff attitudes during a hybrid III implementation-effectiveness trial implmenting cabotegravir + rilpivirine long-acting injectable (CAB + RPV LA) for people living with HIV. Poster presented at: 18th European AIDS Conference; October 27–30, 2021, virtual and London, United Kingdom. Poster PE2/56. Gutner C et al. Healthcare staff perspectives on the implementation of HIV injectable treatment: interim results from the Cabotegravir And Rilpivirine Implementation Study in European Locations (CARISEL). Poster presented at: 18th European AIDS Conference; October 27–30, 2021, virtual and London, United Kingdom. Poster PE2/36. Hocqueloux L et al. Perspectives on the acceptability, appropiateness, feasibility, barriers, and facilitators from patients receiving cabotegravir + rilpivirine long-acting injectable treatment (CAB + RPV LA): interim results from the Cabotegravir And Rilpivirine Implementation Study in European Locations (CARISEL). Poster presented at: 18th European AIDS Conference; October 27–30, 2021, virtual and London, United Kingdom. Calleja-Hernández MA, Martínez-Sesmero JM, Vallejo-Aparicio LA, Hernández-Novoa B, Badia X. en representación del Grupo de estudio CAB + RPV AP MCDA. Contribución de cabotegravir + rilpivirina de acción prolongada al tratamiento de la infección por VIH-1. Farm Hosp. 2022;46(4):208–14. Ministerio de Sanidad. Centros, servicios y establecimientos sanitarios. Centros y Servicios del Sistema Nacional de Salud. Accessed: 01/09/2022. Servicio de Salud. (2017). Resolución de 15 de noviembre de 2017. Diario Oficial de Castilla-La Mancha núm. 226, 22 de noviembre de 2017. Osakidetza-Servicio Vasco de Salud. (2021). Acuerdo de 13 de diciembre de 2021. Boletín Oficial del País Vasco, número 3, 5 de enero de 2022. Additional Declarations Competing interest reported. Laura-Amanda Vallejo Aparicio is employee and holds stocks of GSK group of companies; Victoria Neches García is employee of GSK group of companies; Beatriz Hernández-Novoa is employee and holds stocks of ViiV Healthcare; Gregorio Casado, Ferrán Jodar, Marco Pinel and Daniel Callejo Velasco are employees of IQVIA. IQVIA received fees from ViiV Healthcare for conducting the study. Supplementary Files SupplementaryMaterialQuestionnaireresourceusaLAregimenvsoralART.pdf Cite Share Download PDF Status: Published Journal Publication published 02 Aug, 2024 Read the published version in BMC Infectious Diseases → Version 1 posted Editorial decision: Revision requested 17 May, 2024 Reviews received at journal 15 May, 2024 Reviewers agreed at journal 26 Apr, 2024 Reviews received at journal 18 Apr, 2024 Reviews received at journal 01 Apr, 2024 Reviewers agreed at journal 31 Mar, 2024 Reviewers agreed at journal 30 Mar, 2024 Reviewers invited by journal 30 Mar, 2024 Editor assigned by journal 27 Mar, 2024 Editor invited by journal 12 Mar, 2024 Submission checks completed at journal 12 Mar, 2024 First submitted to journal 17 Jan, 2024 You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-3872460","acceptedTermsAndConditions":true,"allowDirectSubmit":false,"archivedVersions":[],"articleType":"Research Article","associatedPublications":[],"authors":[{"id":278927591,"identity":"0e0a780f-72e6-4491-8670-9901b61cc562","order_by":0,"name":"Laura Amanda Vallejo Aparicio","email":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAZAAAAAyAQMAAABI0h/eAAAABlBMVEX///8AAABVwtN+AAAACXBIWXMAAA7EAAAOxAGVKw4bAAABBElEQVRIie3QP2rDMByG4U8IkkVUqwMhvoKNoFPoFXoFG4OyOFMXQ4eqSyeB13TqFRoKnSUE8eIDFLokS6cMGV3IUIcOyRKbbIXqmX4gvegP4Hl/0NVxpI8GDBNg0J2cLBN1SMSlCZCq3mRYX+8a3CCqrDK78XT2crtK0BTv5xOWi2eNDFGdKrtgcr78kIbo+rPjYrloX0AxUqlyjLn5cjFUlDx1JHwryB4PGJUb5fbMzeKy6kmCXFAGBx60p4C5JIQ0PcnXHR1HFePBRlnNZPwayMR2vYXz7I1si/vJgGd2/a2nYViu4nVTnE9+Re0PHBDdzgYwPftPNUCoLtjveZ73L/wALA5Q3ei2bywAAAAASUVORK5CYII=","orcid":"","institution":"GSK","correspondingAuthor":true,"prefix":"","firstName":"Laura","middleName":"Amanda Vallejo","lastName":"Aparicio","suffix":""},{"id":278927593,"identity":"45f9a6d8-54fe-4dd6-ae4f-56c2c6c24f5e","order_by":1,"name":"Victoria Neches García","email":"","orcid":"","institution":"GSK","correspondingAuthor":false,"prefix":"","firstName":"Victoria","middleName":"Neches","lastName":"García","suffix":""},{"id":278927594,"identity":"b9f6874c-bed3-4638-943d-4ad21d026244","order_by":2,"name":"Beatriz Hernández-Novoa","email":"","orcid":"","institution":"ViiV Healthcare","correspondingAuthor":false,"prefix":"","firstName":"Beatriz","middleName":"","lastName":"Hernández-Novoa","suffix":""},{"id":278927597,"identity":"64261b26-c79e-44bc-bb42-7fa1505a9a9e","order_by":3,"name":"Gregorio Casado","email":"","orcid":"","institution":"IQVIA","correspondingAuthor":false,"prefix":"","firstName":"Gregorio","middleName":"","lastName":"Casado","suffix":""},{"id":278927600,"identity":"bec9ebae-6438-4ab8-884f-d9451b098aa2","order_by":4,"name":"Ferrán Jodar","email":"","orcid":"","institution":"IQVIA","correspondingAuthor":false,"prefix":"","firstName":"Ferrán","middleName":"","lastName":"Jodar","suffix":""},{"id":278927601,"identity":"ee256b26-5373-48e1-87b3-8f34043598f8","order_by":5,"name":"Marco Pinel","email":"","orcid":"","institution":"IQVIA","correspondingAuthor":false,"prefix":"","firstName":"Marco","middleName":"","lastName":"Pinel","suffix":""},{"id":278927602,"identity":"cffe3948-2d8c-4591-881c-114b74a4c870","order_by":6,"name":"Daniel Callejo Velasco","email":"","orcid":"","institution":"IQVIA","correspondingAuthor":false,"prefix":"","firstName":"Daniel","middleName":"Callejo","lastName":"Velasco","suffix":""}],"badges":[],"createdAt":"2024-01-17 09:31:53","currentVersionCode":1,"declarations":"","doi":"10.21203/rs.3.rs-3872460/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-3872460/v1","draftVersion":[],"editorialEvents":[{"content":"https://doi.org/10.1186/s12879-024-09595-4","type":"published","date":"2024-08-02T15:57:36+00:00"}],"editorialNote":"","failedWorkflow":false,"files":[{"id":52709204,"identity":"5f6ac8bc-3216-481d-be9a-259c90e49448","added_by":"auto","created_at":"2024-03-14 19:45:14","extension":"jpg","order_by":1,"title":"Figure 1","display":"","copyAsset":false,"role":"figure","size":107538,"visible":true,"origin":"","legend":"\u003cp\u003eHealthcare resource use estimated by the whole sample\u003c/p\u003e\n\u003cp\u003eART, antiretroviral therapy; CAB + RPV LA, cabotegravir+rilpivirine long-acting.\u003c/p\u003e\n\u003cp\u003e*Significant difference at 95%\u003c/p\u003e","description":"","filename":"Figure1.jpg","url":"https://assets-eu.researchsquare.com/files/rs-3872460/v1/d0a33afbbcfd9f3391e29eba.jpg"},{"id":52709224,"identity":"35ee0a28-0a4b-409c-b686-9c655d680744","added_by":"auto","created_at":"2024-03-14 19:45:16","extension":"jpg","order_by":2,"title":"Figure 2","display":"","copyAsset":false,"role":"figure","size":106418,"visible":true,"origin":"","legend":"\u003cp\u003eHealthcare resource use estimated by the corresponding specialist\u003c/p\u003e\n\u003cp\u003eART, antiretroviral therapy; CAB + RPV LA, cabotegravir+rilpivirine long-acting.\u003c/p\u003e\n\u003cp\u003e*Significant difference at 95%\u003c/p\u003e","description":"","filename":"Figure2.jpg","url":"https://assets-eu.researchsquare.com/files/rs-3872460/v1/aacfbd5c48fac64624e1dc3f.jpg"},{"id":52709222,"identity":"b0e43e7f-27c5-429a-bd0c-23992887e0a2","added_by":"auto","created_at":"2024-03-14 19:45:15","extension":"jpg","order_by":3,"title":"Figure 3","display":"","copyAsset":false,"role":"figure","size":128438,"visible":true,"origin":"","legend":"\u003cp\u003eAnnual costs per patient associated with healthcare resource use estimated by the whole sample\u003c/p\u003e\n\u003cp\u003eART, antiretroviral therapy; CAB + RPV LA, cabotegravir+rilpivirine long-acting.\u003c/p\u003e\n\u003cp\u003e*Significant difference at 95%\u003c/p\u003e","description":"","filename":"Figure3.jpg","url":"https://assets-eu.researchsquare.com/files/rs-3872460/v1/e52607ddb086ed3cb324782b.jpg"},{"id":52709203,"identity":"04f56bfa-9fa9-453f-bf86-f6374184bb5f","added_by":"auto","created_at":"2024-03-14 19:45:14","extension":"jpg","order_by":4,"title":"Figure 4","display":"","copyAsset":false,"role":"figure","size":140664,"visible":true,"origin":"","legend":"\u003cp\u003eAnnual costs per patient associated with healthcare resource use estimated by the corresponding specialist\u003c/p\u003e\n\u003cp\u003eART, antiretroviral therapy; CAB + RPV LA, cabotegravir+rilpivirine long-acting.\u003c/p\u003e\n\u003cp\u003e*Significant difference at 95%\u003c/p\u003e","description":"","filename":"Figure4.jpg","url":"https://assets-eu.researchsquare.com/files/rs-3872460/v1/fbded44477a6051bd24a8cba.jpg"},{"id":61793423,"identity":"9cc71306-dbc3-4e3c-a7e1-68fb14ee9411","added_by":"auto","created_at":"2024-08-05 16:12:22","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":1004403,"visible":true,"origin":"","legend":"","description":"","filename":"manuscript.pdf","url":"https://assets-eu.researchsquare.com/files/rs-3872460/v1/e56a256c-3608-499b-ae3e-a2040f920ba2.pdf"},{"id":52709226,"identity":"19c0579b-c96e-4b1b-88ea-e5f3d316330a","added_by":"auto","created_at":"2024-03-14 19:45:16","extension":"pdf","order_by":6,"title":"","display":"","copyAsset":false,"role":"supplement","size":246065,"visible":true,"origin":"","legend":"","description":"","filename":"SupplementaryMaterialQuestionnaireresourceusaLAregimenvsoralART.pdf","url":"https://assets-eu.researchsquare.com/files/rs-3872460/v1/641191fc0d558231a0e1608a.pdf"}],"financialInterests":"Competing interest reported. Laura-Amanda Vallejo Aparicio is employee and holds stocks of GSK group of companies; Victoria Neches García is employee of GSK group of companies; Beatriz Hernández-Novoa is employee and holds stocks of ViiV Healthcare; Gregorio Casado, Ferrán Jodar, Marco Pinel and Daniel Callejo Velasco are employees of IQVIA. IQVIA received fees from ViiV Healthcare for conducting the study.","formattedTitle":"Potential healthcare resource use and associated costs of every 2 month injectable cabotegravir plus rilpivirine long-acting regimen implementation in the Spanish National Healthcare System compared to daily oral HIV treatments","fulltext":[{"header":"Why carry out this study?","content":"\u003cul\u003e\n \u003cli\u003eMain clinical guidelines in HIV recommend the use of daily oral antiretroviral combinations. Recently, a long-acting regimen consisting of cabotegravir plus rilpivirine (CAB+RPV LA) gluteal intramuscular injections has become available in Spain for maintaining HIV-1 suppression.\u0026nbsp;\u003c/li\u003e\n \u003cli\u003eGiven that the long-acting regimes is administered every 2 months, it is anticipated to have a different patient pathway within the hospital compared to daily oral ART, which may lead to changes in healthcare resources and associated costs needed for HIV treatment.\u003c/li\u003e\n\u003c/ul\u003e\n\u003cp\u003e\u003cstrong\u003eWhat was learned from the study?\u003c/strong\u003e\u003c/p\u003e\n\u003cul\u003e\n \u003cli\u003eThe total annual cost per patient ranged from \u0026euro;2,032 to \u0026euro;2,076 for CAB+RPV LA, and from \u0026euro;2,237 to \u0026euro;2,473 for daily oral ART.\u003c/li\u003e\n \u003cli\u003eThis figures suggest that the implementation of CAB+RPV LA in Spanish NHS hospitals would not translate into increased healthcare resource utilization-related costs associated to a different patient pathway compared to current daily oral ART, being potentially cost-saving.\u0026nbsp;\u003c/li\u003e\n\u003c/ul\u003e"},{"header":"Introduction","content":"\u003cp\u003eThe first cases of AIDS were described in 1981, and over four decades later, HIV remains one of the main public health concerns with 38.4\u0026nbsp;million people currently living with HIV worldwide, 1.7\u0026nbsp;million of them being children, with 1.5\u0026nbsp;million newly acquiring HIV every year and almost 700,000 AIDS-related deaths in 2020 [\u003cspan additionalcitationids=\"CR2\" citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e3\u003c/span\u003e]. In Spain, 151,387 people are estimated to be living with HIV, with an average of over 3,500 new cases diagnosed every year in the last decade, although it has been in decline in the past two years [\u003cspan additionalcitationids=\"CR5\" citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eSurvival of people with HIV (PHIV) has greatly improved in the last couple of decades thanks to the evolution of antiretroviral therapy (ART), resulting in the chronification of the disease [\u003cspan citationid=\"CR7\" class=\"CitationRef\"\u003e7\u003c/span\u003e]. Nowadays, PHIV that are diagnosed early and are capable of taking continuous ART have a life expectancy that approaches that of general population, so their care focus currently should not only be on achieving and maintaining viral suppression, but also on managing age-related comorbidities, the use of concomitant treatments, drug-related toxicity and improving quality of life of people living with HIV (PLHIV) [\u003cspan additionalcitationids=\"CR9 CR10 CR11\" citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR12\" class=\"CitationRef\"\u003e12\u003c/span\u003e]. In 2014 the Joint United Nations Programme on HIV/AIDS (UNAIDS) established the 90-90-90 target: by 2020, 90% of all people living with HIV know their HIV status, 90% of all people diagnosed with HIV receive sustained antiretroviral therapy, and 90% of all people receiving antiretroviral therapy have viral suppression, aiming to reach 95-95-95 initially by 2030 [\u003cspan citationid=\"CR13\" class=\"CitationRef\"\u003e13\u003c/span\u003e] and recently accelerated to 2025 [\u003cspan citationid=\"CR14\" class=\"CitationRef\"\u003e14\u003c/span\u003e]. Also, a \u0026lsquo;fourth 90\u0026rsquo; was deemed necessary in terms of quality of life of people with viral load (VL) suppression would have good health-related quality of life, entailing attention to both comorbidities and self-perceived quality of life, resulting in a more people-centred approach from health systems [\u003cspan citationid=\"CR15\" class=\"CitationRef\"\u003e15\u003c/span\u003e]. Recently this concept has been further evolved by an international multidisciplinary panel of HIV experts agreeing on a consensus statement for the long-term wellbeing of PHIV [\u003cspan citationid=\"CR16\" class=\"CitationRef\"\u003e16\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eUntil recently, all ART regimens recommended by the main clinical guidelines were based on daily oral antiretroviral combinations [\u003cspan additionalcitationids=\"CR18\" citationid=\"CR17\" class=\"CitationRef\"\u003e17\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR19\" class=\"CitationRef\"\u003e19\u003c/span\u003e]. Cabotegravir plus rilpivirine (CAB\u0026thinsp;+\u0026thinsp;RPV) gluteal intramuscular injections administered by a healthcare professional (HCP) is the first and only long acting (LA) regimen available for maintaining HIV-1 suppression. This innovative LA ART authorized in Europe in December 2020 for the treatment of HIV-1 infection in adults who are virologically suppressed, became recently available also in Spain [\u003cspan additionalcitationids=\"CR21 CR22 CR23 CR24\" citationid=\"CR20\" class=\"CitationRef\"\u003e20\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR25\" class=\"CitationRef\"\u003e25\u003c/span\u003e]. This new regimen transforms the treatment paradigm of PHIV, as it is dosed less frequently than daily oral ART, is subject to fewer drug interactions, and may be beneficial or improve the quality of life for individuals with pill fatigue or concerns about disclosure of their HIV status or stigma associated with intake of daily oral medication [\u003cspan citationid=\"CR20\" class=\"CitationRef\"\u003e20\u003c/span\u003e, \u003cspan citationid=\"CR21\" class=\"CitationRef\"\u003e21\u003c/span\u003e, \u003cspan citationid=\"CR23\" class=\"CitationRef\"\u003e23\u003c/span\u003e, \u003cspan citationid=\"CR24\" class=\"CitationRef\"\u003e24\u003c/span\u003e, \u003cspan citationid=\"CR26\" class=\"CitationRef\"\u003e26\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eCAB\u0026thinsp;+\u0026thinsp;RPV LA was evaluated in three phase III randomized, active-controlled, non-inferiority clinical trials: FLAIR [\u003cspan citationid=\"CR27\" class=\"CitationRef\"\u003e27\u003c/span\u003e], ATLAS [\u003cspan citationid=\"CR28\" class=\"CitationRef\"\u003e28\u003c/span\u003e] and ATLAS-2M [\u003cspan citationid=\"CR29\" class=\"CitationRef\"\u003e29\u003c/span\u003e]. The ATLAS and FLAIR trials demonstrated the non-inferiority of CAB\u0026thinsp;+\u0026thinsp;RPV LA at 48 weeks dosed Q4W (monthly) versus daily oral ART (any triple ART for ATLAS or Triumeq\u0026reg; for FLAIR) in both individual trial analysis [adjusted difference in proportion of patients with VL\u0026thinsp;\u0026gt;\u0026thinsp;50 copies/ml: ATLAS: 0.6% (95% CI: \u0026minus;1.2 to 2.5); FLAIR: 0.4% (95% CI: \u0026minus;2.8 to 2.1)] as in the pooled analysis of both [adjusted difference in the proportion of patients with VL\u0026thinsp;\u0026gt;\u0026thinsp;50 copies/mL: 0.2% (CI 95%: \u0026minus;1.4 to 1.7)]. Subsequently, the phase IIIb ATLAS-2M trial demonstrated at 48 weeks the non-inferiority of CAB\u0026thinsp;+\u0026thinsp;RPV LA Q8W (every 2 months) versus Q4W dosing [adjusted difference in the proportion of patients with VL\u0026thinsp;\u0026gt;\u0026thinsp;50 copies/mL: 0.8% (95% CI: \u0026minus;0.6 to 2.2)]. CAB\u0026thinsp;+\u0026thinsp;RPV LA dosed Q4W or Q8W maintained virologic suppression (HIV RNA\u0026thinsp;\u0026lt;\u0026thinsp;50 c/mL) at 48 weeks in 94% (n\u0026thinsp;=\u0026thinsp;1,531/1,636) of the participants in the three phase III/IIIb trials. The safety profile of CAB\u0026thinsp;+\u0026thinsp;RPV LA in the ATLAS and FLAIR trials was comparable to that of current oral ART. Injection Site Reactions (ISRs) occurred in 25% of injections, the majority (98%) were mild/moderate in grade, lasting a median of 3 days, and the number of discontinuations for ISRs was very low (\u0026lt;\u0026thinsp;2% of patients). 97\u0026ndash;99% of the participants in the phase III/IIIb clinical trials preferred CAB\u0026thinsp;+\u0026thinsp;RPV LA vs daily oral ART supporting the patient preference for a long-acting treatment [\u003cspan citationid=\"CR30\" class=\"CitationRef\"\u003e30\u003c/span\u003e, \u003cspan citationid=\"CR31\" class=\"CitationRef\"\u003e31\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eConsidering frequency of administration every 2 months vs current recommended daily oral ART regimens for virologically suppressed PHIV, the new long-acting CAB\u0026thinsp;+\u0026thinsp;RPV injectable regimen is anticipated to have a different patient pathway within the Spanish National Health System (NHS) hospitals when implemented, compared to daily oral ART [\u003cspan additionalcitationids=\"CR33\" citationid=\"CR32\" class=\"CitationRef\"\u003e32\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR34\" class=\"CitationRef\"\u003e34\u003c/span\u003e], which may lead to changes in the healthcare resources and its associated costs needed for its administration.\u003c/p\u003e \u003cp\u003eThe objective of this study was to evaluate the potential differences in healthcare resource use and its impact on associated costs resulting from the implementation of CAB\u0026thinsp;+\u0026thinsp;RPV LA compared to current daily oral ART from the perspective of Spanish NHS hospitals.\u003c/p\u003e"},{"header":"Methods","content":"\u003cp\u003eWe performed a cross-sectional study consisting of online quantitative interviews (CAWI, Computer Assisted Web Interviewing) of HCPs involved in hospital HIV treatment and daily care: infectious disease specialists, hospital pharmacists, and nurses, followed by a cost analysis based on the results obtained.\u003c/p\u003e \u003cp\u003eHCPs were recruited by phone and then completed the online questionnaire not exceeding 25 minutes in length. In the CAWI, after presenting, HCPs were asked about their perception of the potential differences in the healthcare resource utilization (HRU) between oral ART and CAB\u0026thinsp;+\u0026thinsp;RPV LA; precisely, estimations on the annual number of visits per patient required to the infectious disease specialist, to the hospital pharmacy and to the nursing team were collected. The interviews were carried out between May 19th and June 3rd, 2022.\u003c/p\u003e \u003cp\u003eAlthough the focus was HRU and its associated costs, to fully understand how the implementation of the new injectable regimen was perceived by the HCPs, other concepts were asked in the CAWI, such as the general assessment of CAB\u0026thinsp;+\u0026thinsp;RPV LA, potential administration management and logistics of CAB\u0026thinsp;+\u0026thinsp;RPV LA, staff and capacity of the hospital, and training or information needs from the patient.\u003c/p\u003e \u003cp\u003eAll interviews were conducted considering the current regulation on the protection of personal data and pharmacovigilance. Given that answers were based on estimations/opinions and no patient-related information was included, there was no need for an approval from an Ethics Committee. HCPs involved received economic compensation for their participation in the project.\u003c/p\u003e \u003cp\u003eResponses to the interviews were collected in a database and analysed with Gandia BarbWin and Microsoft Excel. Qualitative answers were assessed as the frequency of occurrence over the total number of answers for the question, and quantitative answers as averages and their 95% confidence interval (95% CI).\u003c/p\u003e \u003cp\u003eRegarding HRU, HCPs were asked about their estimation on the number of times that a virologically suppressed PHIV on treatment with ART or with CAB\u0026thinsp;+\u0026thinsp;RPV LA would visit the infectious disease specialist office, the hospital pharmacy, and the nursing team, in a 12-month period. At the time of the survey, CAB\u0026thinsp;+\u0026thinsp;RPV LA was not yet commercialized in Spain, but several HCPs have had previous experience from clinical trials. Questions about visits to hospital pharmacy and nursing team were disaggregated by therapeutic objective (routine control and follow-up, specific adherence check-ins, patient counselling\u0026hellip;). Assuming that more than one therapeutic objective can be covered in each visit, the maximum number of visits estimated by each specialist for both nursing and hospital pharmacy was obtained.\u003c/p\u003e \u003cp\u003eThe questionnaire used in the CAWI is available as Supplementary Material.\u003c/p\u003e \u003cp\u003eFrom the information obtained on HRU estimates in the CAWI, unit costs from official tariffs published by the Autonomous Regions of Spain, updated to \u0026euro; 2,022 through Spanish Consumer Price Index data [\u003cspan citationid=\"CR35\" class=\"CitationRef\"\u003e35\u003c/span\u003e], were used to perform the cost analysis. The unitary cost of each resource was multiplied by the frequency of use of each resource estimated by each interviewee (individual data) for each regimen, according to the following formula:\u003cdiv id=\"Equa\" class=\"Equation\"\u003e\u003cdiv format=\"TEX\" class=\"mathdisplay\" id=\"FileID_Equa\" name=\"EquationSource\"\u003e\n$$Total costs={HRU}_{1}*{unit cost}_{1}+{HRU}_{2}*{unit cost}_{2}+\\dots +{HRU}_{n}*{unit cost}_{n}$$\u003c/div\u003e\u003c/div\u003e\u003c/p\u003e \u003cp\u003ewhere \u003cem\u003eHRU\u003c/em\u003e represents the estimated frequency a given healthcare resource has been used by each regimen, and \u003cem\u003eunit cost\u003c/em\u003e the cost associated to each use of a given resource by each regimen.\u003c/p\u003e \u003cp\u003eSubsequently, the average cost was calculated based on two methodologies: HRU from the visits estimated by the whole sample of respondents (i.e., estimated number of visits to the infectious disease specialist based on answers from infectious disease specialists, hospital pharmacists, and nurses), and HRU estimated by the corresponding specialist (i.e., estimated number of visits to the infectious disease specialist based solely on answers received specifically from infectious disease specialists).\u003c/p\u003e"},{"header":"Results","content":"\u003cp\u003eA total of 120 HCPs were interviewed: 40 Infectious disease specialists, 40 hospital pharmacists, and 40 nurses, with a mean (standard deviation) of 194 (174) PHIV seen monthly and 19.9 (8.3) years of experience with injectable treatments. A summary of the key characteristics of the sample interviewed is shown in Table\u0026nbsp;\u003cspan refid=\"Tab1\" class=\"InternalRef\"\u003e1\u003c/span\u003e.\u003c/p\u003e \u003cp\u003e \u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab1\" border=\"1\"\u003e \u003ccaption language=\"En\"\u003e \u003cdiv class=\"CaptionNumber\"\u003eTable 1\u003c/div\u003e \u003cdiv class=\"CaptionContent\"\u003e \u003cp\u003eCharacteristics of the sample interviewed\u003c/p\u003e \u003c/div\u003e \u003c/caption\u003e \u003ccolgroup cols=\"5\"\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c3\" colnum=\"3\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c4\" colnum=\"4\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c5\" colnum=\"5\"\u003e\u003c/div\u003e \u003cthead\u003e \u003ctr\u003e \u003cth align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/th\u003e \u003cth align=\"left\" colname=\"c2\"\u003e \u003cp\u003eInfectious disease specialist\u003c/p\u003e \u003cp\u003e(n\u0026thinsp;=\u0026thinsp;40)\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c3\"\u003e \u003cp\u003eHospital pharmacist\u003c/p\u003e \u003cp\u003e(n\u0026thinsp;=\u0026thinsp;40)\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c4\"\u003e \u003cp\u003eNurse\u003c/p\u003e \u003cp\u003e(n\u0026thinsp;=\u0026thinsp;40)\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c5\"\u003e \u003cp\u003eTotal\u003c/p\u003e \u003cp\u003e(n\u0026thinsp;=\u0026thinsp;120)\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003c/thead\u003e \u003ctbody\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eHIV patients seen monthly\u003c/b\u003e, mean (SD)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e142 (74)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e321 (218)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e117 (117)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e194 (174)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eYears of experience with injectable treatments\u003c/b\u003e, mean (SD)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e21.3 (7.8)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e19.3 (6.8)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e19.2 (10.1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e19.9 (8.3)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"5\" nameend=\"c5\" namest=\"c1\"\u003e \u003cp\u003e\u003cb\u003eAutonomous region\u003c/b\u003e, n (%)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eAndaluc\u0026iacute;a\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e2 (5%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e6 (15%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e5 (13%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e13 (11%)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eArag\u0026oacute;n\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e1 (3%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e0 (0%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0 (0%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e1 (1%)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003ePrincipado de Asturias\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e1 (3%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e0 (0%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e1 (3%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e2 (2%)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eIslas Baleares\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e0 (0%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e2 (5%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0 (0%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e2 (2%)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eCanarias\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e0 (0%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e2 (5%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e1 (3%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e3 (3%)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eCantabria\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e1 (3%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e1 (3%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e1 (3%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e3 (3%)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eCastilla - La Mancha\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e3 (8%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e2 (5%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0 (0%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e5 (4%)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eCastilla y Le\u0026oacute;n\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e1 (3%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e1 (3%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0 (0%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e2 (2%)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eCatalu\u0026ntilde;a\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e9 (23%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e9 (23%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e8 (20%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e26 (22%)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eComunidad Valenciana\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e5 (13%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e5 (13%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e6 (15%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e16 (13%)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eExtremadura\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e1 (3%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e0 (0%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0 (0%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e1 (1%)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eGalicia\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e3 (8%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e2 (5%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e1 (3%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e6 (5%)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eComunidad de Madrid\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e13 (33%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e8 (20%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e14 (35%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e35 (29%)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eRegi\u0026oacute;n de Murcia\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e0 (0%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e0 (0%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e3 (8%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e3 (3%)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eComunidad Foral de Navarra\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e0 (0%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e1 (3%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0 (0%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e1 (1%)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003ePa\u0026iacute;s Vasco\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e0 (0%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e1 (3%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0 (0%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e1 (1%)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"5\" nameend=\"c5\" namest=\"c1\"\u003e \u003cp\u003e\u003cb\u003eHospital size\u003c/b\u003e, n (%)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eLarge (\u0026gt;\u0026thinsp;500 beds)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e24 (60%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e30 (75%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e27 (68%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e81 (68%)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eMedium (\u0026ge;\u0026thinsp;200 \u0026amp; \u0026le;500 beds)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e16 (40%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e10 (25%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e13 (33%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e39 (33%)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eSmall (\u0026lt;\u0026thinsp;200 beds)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e0 (0%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e0 (0%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0 (0%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e0 (0%)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003c/tbody\u003e \u003c/colgroup\u003e \u003ctfoot\u003e \u003ctr\u003e\u003ctd colspan=\"5\"\u003eN, sample included; SD, standard deviation.\u003c/td\u003e\u003c/tr\u003e \u003c/tfoot\u003e \u003c/table\u003e\u003c/div\u003e \u003c/p\u003e \u003cp\u003eRegarding the general assessment of CAB\u0026thinsp;+\u0026thinsp;RPV LA, this new injectable regimen scored an 8.7 in an increasing scale from 1 to 10 measuring the level of interest among HCPs, with 71% of the specialists being aware of its clinical development. Fatigue associated with daily oral ART were mentioned by 61% of the HCPs as the profile that could benefit the most from CAB\u0026thinsp;+\u0026thinsp;RPV LA, followed by suboptimal adherence to oral ART (59%) and emotional difficulties associated with oral ART (56%). The main drivers identified for the implementation of CAB\u0026thinsp;+\u0026thinsp;RPV LA were the improvement of therapeutic compliance (73%), decreased stigma associated with oral ART (72%) and greater logistical flexibility (68%). As for the barriers of implementing CAB\u0026thinsp;+\u0026thinsp;RPV LA, 72% of the specialists mentioned the injection procedure, 59% the extra workload for the nursing team and 56% the need for the PHIV to visit the hospital every 2 months. Finally, up to 74% of the HCPs considered that CAB\u0026thinsp;+\u0026thinsp;RPV LA would improve the people\u0026rsquo;s quality of life compared to oral ART (score: 8.1 out of 10).\u003c/p\u003e \u003cp\u003eIn general, 66% of the HCPs declared not having any concern regarding the implementation of CAB\u0026thinsp;+\u0026thinsp;RPV LA, and those who did (34%), mentioned the work overload of the nursing team (22%) and the economic cost (22%) as their main worries.\u003c/p\u003e \u003cp\u003eAs to the implications on staff and capacity of the hospital, 41% of the HCPs indicated that new resources would be needed in the hospital for the administration of CAB\u0026thinsp;+\u0026thinsp;RPV LA, mostly through increasing the nursing staff (63%).\u003c/p\u003e \u003cp\u003eRegarding materials to be shared with PHIV, 88% of the HCPs demanded information about adverse events and 79% information about injection site reactions and importance of maintaining an optimum adherence, being applications (71%), printed materials (70%) and websites (54%) the preferred platforms with which to share the information.\u003c/p\u003e \u003cp\u003eFinally, in terms of HRU, the estimated average (95% CI) annual visits per patient reported by the total sample of HCPs for CAB\u0026thinsp;+\u0026thinsp;RPV LA vs. daily oral ART respectively were 3.3 (95% CI: 2.8 to 3.7) vs. 3.7 (95% CI: 3.1 to 4.3) for visits to infectious disease specialist; 4.4 (95% CI: 4.0 to 4.8) vs. 6.2 (95% CI: 5.8 to 6.7) to the hospital pharmacy; and 6.1 (95% CI: 5.4 to 6.8) vs. 3.9 (95% CI: 3.4 to 4.3) to the nursing team (Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003e). When considering the results as reported by the corresponding specialist, the estimated average (95% CI) annual visits per patient for CAB\u0026thinsp;+\u0026thinsp;RPV LA vs. daily oral ART respectively were 3.0 (95% CI: 2.5 to 3.4) vs. 3.2 (95% CI: 2.6 to 3.7); 4.8 (95% CI: 4.2 to 5.4) vs. 5.8 (95% CI: 5.3 to 6.3); and 6.9 (95% CI: 4.8 to 9.0) vs. 4.9 (95% CI: 3.9 to 5.9) (Fig.\u0026nbsp;\u003cspan refid=\"Fig2\" class=\"InternalRef\"\u003e2\u003c/span\u003e). Regarding visits to infectious disease specialists\u0026rsquo; little to no differences were expected by HCPs, not being statistically significant. A shift from hospital pharmacy to nursing team visits, with CAB\u0026thinsp;+\u0026thinsp;RPV LA compared to daily oral ART, within the hospital was observed. Differences in annual visits per patient to hospital pharmacy and nursing team between regimens were statistically significant at a 95% confidence level on both methodologies.\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003cp\u003eUnit costs for each resource, updated to 2022, are shown in Table\u0026nbsp;\u003cspan refid=\"Tab2\" class=\"InternalRef\"\u003e2\u003c/span\u003e. When applying the unit costs to each HRU, the estimation by total sample of HCPs led to a total annual cost per patient (95% CI) of 2,076 \u0026euro; (95% CI: 1,887 \u0026euro; to 2,265 \u0026euro;) vs. 2,473 \u0026euro; (95% CI: 2,202 \u0026euro; to 2,745 \u0026euro;) for CAB\u0026thinsp;+\u0026thinsp;RPV LA vs. daily oral ART, being 2,032 \u0026euro; (95% CI: 1,966 \u0026euro; to 2,099 \u0026euro;) vs. 2,237 \u0026euro; (95% CI: 2,162 \u0026euro; to 2,312 \u0026euro;), respectively, after adjusting by the corresponding specialist. Differences in total annual costs per patient between regimens were statistically significant at a 95% confidence level on both methodologies. Detailed results from the cost analysis for each methodology are shown in and Fig.\u0026nbsp;\u003cspan refid=\"Fig3\" class=\"InternalRef\"\u003e3\u003c/span\u003e and Fig.\u0026nbsp;\u003cspan refid=\"Fig4\" class=\"InternalRef\"\u003e4\u003c/span\u003e.\u003c/p\u003e \u003cp\u003e \u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab2\" border=\"1\"\u003e \u003ccaption language=\"En\"\u003e \u003cdiv class=\"CaptionNumber\"\u003eTable 2\u003c/div\u003e \u003cdiv class=\"CaptionContent\"\u003e \u003cp\u003eUnit costs of the healthcare resources\u003c/p\u003e \u003c/div\u003e \u003c/caption\u003e \u003ccolgroup cols=\"3\"\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e \u003cdiv align=\"char\" char=\".\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c3\" colnum=\"3\"\u003e\u003c/div\u003e \u003cthead\u003e \u003ctr\u003e \u003cth align=\"left\" colname=\"c1\"\u003e \u003cp\u003eConcept\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c2\"\u003e \u003cp\u003eUnit cost (\u0026euro; 2022)\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c3\"\u003e \u003cp\u003eSource\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003c/thead\u003e \u003ctbody\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eVisits to the infectious disease specialist\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e370.42 \u0026euro;\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eServicio de Salud (2017). Diario Oficial de Castilla-La Mancha n\u0026uacute;m. 226 [\u003cspan citationid=\"CR42\" class=\"CitationRef\"\u003e42\u003c/span\u003e]\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eVisits to the hospital pharmacy\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e165.00 \u0026euro;\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eOsakidetza-Servicio Vasco de Salud (2021). Bolet\u0026iacute;n Oficial del Pa\u0026iacute;s Vasco, n\u0026uacute;mero 3 [\u003cspan citationid=\"CR43\" class=\"CitationRef\"\u003e43\u003c/span\u003e]\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eVisits to the nursing team\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e22.00 \u0026euro;\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eOsakidetza-Servicio Vasco de Salud (2021). Bolet\u0026iacute;n Oficial del Pa\u0026iacute;s Vasco, n\u0026uacute;mero 3 [\u003cspan citationid=\"CR43\" class=\"CitationRef\"\u003e43\u003c/span\u003e]\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003c/tbody\u003e \u003c/colgroup\u003e \u003c/table\u003e\u003c/div\u003e \u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003cp\u003eDespite the expected shift in the number of visits from hospital pharmacists to nursing teams, when translated to costs, CAB\u0026thinsp;+\u0026thinsp;RPV LA did not incur in increased HRU-related total costs due to its implementation within the hospital\u0026rsquo;s PHIV pathways compared to daily oral ART regimes, even being potentially cost-saving.\u003c/p\u003e"},{"header":"Discussion","content":"\u003cp\u003eCAB\u0026thinsp;+\u0026thinsp;RPV LA is the first and only innovative ART regimen administered every 2 months through HCP-administered intramuscular injections that has shown to be non-inferior to current daily oral ART options [\u003cspan additionalcitationids=\"CR28\" citationid=\"CR27\" class=\"CitationRef\"\u003e27\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR29\" class=\"CitationRef\"\u003e29\u003c/span\u003e, \u003cspan citationid=\"CR36\" class=\"CitationRef\"\u003e36\u003c/span\u003e]. Being a new paradigm in HIV treatment and an HCP-administered injectable regimen, the implementation of CAB\u0026thinsp;+\u0026thinsp;RPV LA may result in a different patient pathway for PHIV within NHS hospitals [\u003cspan citationid=\"CR23\" class=\"CitationRef\"\u003e23\u003c/span\u003e, \u003cspan citationid=\"CR26\" class=\"CitationRef\"\u003e26\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eOverall, HCPs anticipated that the implementation of CAB\u0026thinsp;+\u0026thinsp;RPV LA may transfer hospital pharmacy visits to nursing team visits, compared to current practices with daily oral ART. The costs analysis showed that these changes in the patient pathway for CAB\u0026thinsp;+\u0026thinsp;RPV LA administration with regards of the number of visits could lead to savings of approximately 200\u0026ndash;400 \u0026euro; per patient per year compared to daily oral ART, due to the reduction in visits to the hospital pharmacist, that would outweigh the increase in visits to the nursing team. These results highlight that the implementation of CAB\u0026thinsp;+\u0026thinsp;RPV LA in the NHS hospitals may not incur in increased HRU-related costs.\u003c/p\u003e \u003cp\u003eIn the present study, the main barriers detected by HCPs for implementing CAB\u0026thinsp;+\u0026thinsp;RPV LA were the injection procedure, the extra workload for the nursing team and the need to visit the hospital every 2 months. These results are very similar to the findings from the CARISEL study, a phase IIIb hybrid implementation-effectiveness trial that examined the acceptability, appropriateness and feasibility of CAB\u0026thinsp;+\u0026thinsp;RPV LA in Europe, where the increased number of visits, increase in staff workload and potential discomfort of injection were identified as the main barriers by staff HCPs at baseline [\u003cspan citationid=\"CR37\" class=\"CitationRef\"\u003e37\u003c/span\u003e, \u003cspan citationid=\"CR38\" class=\"CitationRef\"\u003e38\u003c/span\u003e]. However, at month 5, as staff gained experience, there was an average decrease of 43% in the proportion of staff HCPs reporting these barriers [\u003cspan citationid=\"CR37\" class=\"CitationRef\"\u003e37\u003c/span\u003e, \u003cspan citationid=\"CR38\" class=\"CitationRef\"\u003e38\u003c/span\u003e]. Also, visiting the hospital every 2 months, identified as a barrier by the HCPs in our study, was considered acceptable by almost 98% of the CARISEL patient study participants [\u003cspan citationid=\"CR39\" class=\"CitationRef\"\u003e39\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eStaffing and workload concerns were among the most mentioned issues in the interviews, both for the CAB\u0026thinsp;+\u0026thinsp;RPV LA regimen itself and its implementation. Results from CARISEL study showed that mean appointment duration was reduced by 30.4% between month 1 and month 6, meaning that healthcare professionals have a steep learning curve and the initial increase in workload is quickly adjusted [\u003cspan citationid=\"CR39\" class=\"CitationRef\"\u003e39\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eIn a prior study, a multidisciplinary expert panel composed by the main agents involved in PHIV healthcare (the three profiles involved in the current study plus healthcare evaluators and patient association representatives) assessed the added value contribution of CAB\u0026thinsp;+\u0026thinsp;RPV LA to management of HIV in Spain compared to daily oral single-tablet regimens using a MCDA (Multi-Criteria Decision Analysis) methodology [\u003cspan citationid=\"CR40\" class=\"CitationRef\"\u003e40\u003c/span\u003e]. Findings were in line with those reported in the present study, as therapeutic benefit of CAB\u0026thinsp;+\u0026thinsp;RPV LA was highly valued, as the potential benefit in adherence and stigma-related issues may improve overall quality of life for PHIV [\u003cspan citationid=\"CR40\" class=\"CitationRef\"\u003e40\u003c/span\u003e]. The potential implementation of CAB\u0026thinsp;+\u0026thinsp;RPV LA was also perceived as positive, and most of the clinical experts considered that the NHS hospitals are prepared for the correct use and implementation of CAB\u0026thinsp;+\u0026thinsp;RPV LA [\u003cspan citationid=\"CR40\" class=\"CitationRef\"\u003e40\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eThis study has some limitations. First, as CAB\u0026thinsp;+\u0026thinsp;RPV LA was not yet commercially available in Spain at the time of the study, the results rely on previous experience in clinical trials and perceptions of the HCPs included. However, this could only be further addressed in the future with real-world evidence studies regarding CAB\u0026thinsp;+\u0026thinsp;RPV LA implementation. Also, the hospitals included in the analysis are only a sample and might not be representative of the whole universe of hospitals in the Spanish NHS. The final sample of HCPs might also be unbalanced in terms of the representativeness of HCPs across all regions in Spain. It is also worth noting that most of the HCPs worked in large hospitals (\u0026gt;\u0026thinsp;500 beds), representing about 66% of the total amount of large hospitals in Spain, while only 17% of the medium (\u0026ge;\u0026thinsp;200 - \u0026le;500 beds), and 0% of the small (\u0026lt;\u0026thinsp;200 beds) hospitals were included [\u003cspan citationid=\"CR41\" class=\"CitationRef\"\u003e41\u003c/span\u003e]. Regarding the cost analysis, only visits to infectious disease specialist, hospital pharmacy and nursing team were considered which could be a simplification of the total healthcare resources needed for each treatment pathway for a long-acting injectable vs daily oral ART; however, these were highlighted as the most important resources in terms of human resources. Finally, unitary costs were retrieved from official tariffs published by two Autonomous Regions of Spain, which may not be representative at the national level, but in the absence of National data this was the best approach as done in prior economic studies published in Spain.\u003c/p\u003e \u003cp\u003e To the best of our knowledge, this is the first study evaluating the potential economic impact of implementing CAB\u0026thinsp;+\u0026thinsp;RPV LA vs daily oral ART for the treatment PHIV in Spain using a representative sample of relevant HCPs.\u003c/p\u003e \u003cp\u003eResults from this study suggest that the implementation of CAB\u0026thinsp;+\u0026thinsp;RPV LA in Spanish NHS hospitals would not incur in increased HRU-related costs associated to a different patient pathway compared to current daily oral ART, being potentially neutral or even cost-saving. Future real-world evidence studies would complement our results.\u003c/p\u003e"},{"header":"Declarations","content":"\u003cp\u003eAcknowledgments\u003c/p\u003e\n\u003cp\u003eThe authors would like to thank the healthcare professionals involved in the interviews for their willingness to participate and their input.\u003c/p\u003e\n\u003cp\u003eAll authors contributed to the study conception and design. Material preparation, data collection and analysis were performed by all authors. The first draft of the manuscript was written by all authors and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.\u003c/p\u003e\n\u003cp\u003eFunding\u003c/p\u003e\n\u003cp\u003eThis work was funded by ViiV Healthcare.\u003c/p\u003e\n\u003cp\u003eConflict of interests\u003c/p\u003e\n\u003cp\u003eLaura-Amanda Vallejo Aparicio is employee and holds stocks of GSK group of companies; Victoria Neches Garc\u0026iacute;a is employee of GSK group of companies; Beatriz Hern\u0026aacute;ndez-Novoa is employee and holds stocks of ViiV Healthcare; Gregorio Casado, Ferr\u0026aacute;n Jodar, Marco Pinel and Daniel Callejo Velasco are employees of IQVIA. IQVIA received fees from ViiV Healthcare for conducting the study.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eEthics\u003c/p\u003e\n\u003cp\u003eAll interviews were conducted considering the current regulation on the protection of personal data and pharmacovigilance and in accordance to the EPHMRA Code of Conduct 2022. Given that this study met all requirements to be considered a market research study, according to the EPHMRA Code of Conduct 2022 it did not require Clinical Research Ethics Committee or Independent Review Board approval. HCPs involved received economic compensation for their participation in the project.\u003c/p\u003e\n\u003cp\u003eData Availability\u003c/p\u003e\n\u003cp\u003eThe datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.\u003c/p\u003e"},{"header":"References","content":"\u003col\u003e\u003cli\u003e\u003cspan\u003eGlobal Report. UNAIDS report on the global AIDS epidemic 2021. Available at: \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://www.unaids.org/sites/default/files/media_asset/UNAIDS_FactSheet_en.pdf\u003c/span\u003e\u003cspan address=\"https://www.unaids.org/sites/default/files/media_asset/UNAIDS_FactSheet_en.pdf\" targettype=\"URL\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eUnited Nations. World Leaders in General Assembly Adopt Political Declaration Pledging Urgent, Transformative Action to Stop Global AIDS Epidemic by 2030 [press release]. Available at: \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://press.un.org/en/2021/ga12333.doc.htm\u003c/span\u003e\u003cspan address=\"https://press.un.org/en/2021/ga12333.doc.htm\" targettype=\"URL\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eCenters for Disease Control (CDC). Pneumocystis pneumonia\u0026ndash;Los Angeles. MMWR Morb Mortal Wkly Rep. 1981;30(21):250\u0026ndash;2.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMinisterio de Sanidad. Vigilancia epidemiol\u0026oacute;gica del VIH y SIDA en Espa\u0026ntilde;a 2020. Actualizaci\u0026oacute;n 30 de junio de 2021. November 2021. Available at: \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://www.sanidad.gob.es/ciudadanos/enfLesiones/enfTransmisibles/sida/vigilancia/Informe_VIH_SIDA_WEB.pdf\u003c/span\u003e\u003cspan address=\"https://www.sanidad.gob.es/ciudadanos/enfLesiones/enfTransmisibles/sida/vigilancia/Informe_VIH_SIDA_WEB.pdf\" targettype=\"URL\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eUnidad de vigilancia del VIH, ITS y hepatitis. Actualizaci\u0026oacute;n del Continuo de Atenci\u0026oacute;n del VIH en Espa\u0026ntilde;a, 2017\u0026ndash;2019. Madrid: Centro Nacional de Epidemiolog\u0026iacute;a \u0026ndash; Instituto de Salud Carlos III / Plan Nacional sobre el Sida \u0026ndash; Direcci\u0026oacute;n General de Salud P\u0026uacute;blica. 2020. Disponible en: \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://www.sanidad.gob.es/ciudadanos/enfLesiones/enfTransmisibles/sida/vigilancia/ESTIMACION_DEL_CONTINUO_DE_ATENCIoN_DEL_VIH_EN_ESPAnA_Nov2020.pdf\u003c/span\u003e\u003cspan address=\"https://www.sanidad.gob.es/ciudadanos/enfLesiones/enfTransmisibles/sida/vigilancia/ESTIMACION_DEL_CONTINUO_DE_ATENCIoN_DEL_VIH_EN_ESPAnA_Nov2020.pdf\" targettype=\"URL\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e [Acceso: febrero 2023].\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eDIRECCI\u0026Oacute;N GENERAL DE SALUD P\u0026Uacute;BLICA. VIGILANCIA EPIDEMIOL\u0026Oacute;GICA DEL, VIH y SIDA, EN ESPA\u0026Ntilde;A. 2021 \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://www.isciii.es/QueHacemos/Servicios/VigilanciaSaludPublicaRENAVE/EnfermedadesTransmisibles/Documents/VIH/informes%20de%20vigilancia%20VIH%20y%20sida%20anteriores/Informe%20VIH_SIDA_2022_CCAA.pdf\u003c/span\u003e\u003cspan address=\"https://www.isciii.es/QueHacemos/Servicios/VigilanciaSaludPublicaRENAVE/EnfermedadesTransmisibles/Documents/VIH/informes%20de%20vigilancia%20VIH%20y%20sida%20anteriores/Informe%20VIH_SIDA_2022_CCAA.pdf\" targettype=\"URL\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eGueler A, Moser A, Calmy A, G\u0026uuml;nthard HF, Bernasconi E, Furrer H, et al. Life expectancy in HIV-positive persons in Switzerland: matched comparison with general population. Aids. 2017;31(3):427\u0026ndash;36. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1097/qad.0000000000001335\u003c/span\u003e\u003cspan address=\"10.1097/qad.0000000000001335\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e. Epub 2016/11/11.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eWandeler G, Johnson LF, Egger M. Trends in life expectancy of HIV-positive adults on antiretroviral therapy across the globe: comparisons with general population. Curr Opin HIV AIDS. 2016;11(5):492\u0026ndash;500. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1097/coh.0000000000000298\u003c/span\u003e\u003cspan address=\"10.1097/coh.0000000000000298\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e. Epub 2016/06/03.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eSchouten J, Wit FW, Stolte IG, Kootstra NA, van der Valk M, Geerlings SE, et al. Cross-sectional comparison of the prevalence of age-associated comorbidities and their risk factors between HIV-infected and uninfected individuals: the AGEhIV cohort study. Clin Infect Dis. 2014;59(12):1787\u0026ndash;97. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1093/cid/ciu701\u003c/span\u003e\u003cspan address=\"10.1093/cid/ciu701\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e. Epub 2014/09/04.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eAlthoff KN, Smit M, Reiss P, Justice AC. HIV and ageing: improving quantity and quality of life. Curr Opin HIV AIDS. 2016;11(5):527\u0026ndash;36. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1097/coh.0000000000000305\u003c/span\u003e\u003cspan address=\"10.1097/coh.0000000000000305\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e. Epub 2016/07/02.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eGimeno-Gracia M, S\u0026aacute;nchez-Rubio-Ferr\u0026aacute;ndez J, Robustillo-Cort\u0026eacute;s MLA, Morillo-Verdugo R. Prevalence of polypharmacy and pharmacotherapy complexity in elderly people living with HIV in Spain. POINT study. Farm Hosp. 2020;44(4):127\u0026ndash;34. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.7399/fh.11367\u003c/span\u003e\u003cspan address=\"10.7399/fh.11367\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e. Epub 2020/07/11.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eCollaboration Antiretroviral Therapy Cohort. Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies. Lancet HIV. 2017;4:e349\u0026ndash;56.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eJoint United Nations Programme on HIV/AIDS (UNAIDS). Fast-Track: ending the AIDS epidemic by 2030. 2014.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eJoint United Nations Programme on HIV/AIDS (UNAIDS). 2025 AIDS TARGETS. Available at: https://aidstargets2025.unaids.org/# [Accessed: march 2023]. 2014.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eLazarus JV, Safreed-Harmon K, Barton SE, Costagliola D, Dedes N, del Amo Valero J, et al. Beyond viral suppression of HIV \u0026ndash; the new quality of life frontier. BMC Med. 2016;14(1):94. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1186/s12916-016-0640-4\u003c/span\u003e\u003cspan address=\"10.1186/s12916-016-0640-4\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eConsensus statement on the role of health systems in advancing the long-term well-being of people living with HIV. NATURE COMMUNICATIONS. (2021) 12:4450. Available at: \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1038/s41467-021-24673-w\u003c/span\u003e\u003cspan address=\"10.1038/s41467-021-24673-w\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003ePanel de expertos de GeSIDA y Divisi\u0026oacute;n de control de VIH, ITS, Hepatitis virales y Tuberculosis. Plan Nacional sobre el Sida. (2022) Documento de consenso de GeSIDA/Plan Nacional sobre el SIDA respecto al tratamiento antirretroviral en adultos infectados por el virus de la inmunodeficiencia humana. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://gesida-seimc.org/wp-content/uploads/2022/05/GuiaGeSIDAPlanNacionalSobreElSidaRespectoAlTratamientoAntirretroviralEnAdultosInfectadosPorElVirusDeLaInmunodeficienciaHumanaActualizacionEnero2022.pdf\u003c/span\u003e\u003cspan address=\"https://gesida-seimc.org/wp-content/uploads/2022/05/GuiaGeSIDAPlanNacionalSobreElSidaRespectoAlTratamientoAntirretroviralEnAdultosInfectadosPorElVirusDeLaInmunodeficienciaHumanaActualizacionEnero2022.pdf\" targettype=\"URL\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eEuropean AIDS Clinical Society (EACS). (2021) EACS Guidelines version 11.0, October 2021. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://www.eacsociety.org/media/final2021eacsguidelinesv11.0_oct2021.pdf\u003c/span\u003e\u003cspan address=\"https://www.eacsociety.org/media/final2021eacsguidelinesv11.0_oct2021.pdf\" targettype=\"URL\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eGandhi RT, Bedimo R, Hoy JF, Landovitz RJ, Smith DM, Eaton EF, et al. Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2022 Recommendations of the International Antiviral Society\u0026ndash;USA Panel. JAMA. 2023;329(1):63\u0026ndash;84. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1001/jama.2022.22246\u003c/span\u003e\u003cspan address=\"10.1001/jama.2022.22246\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBares SH, et al. Curr Opin HIV AIDS. 2022;17(1):22\u0026ndash;31.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eRana AI, et al. Drugs. 2020;80(6):535\u0026ndash;45.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eEuropean Medicines Agency. VOCABRIA Available at: \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://www.ema.europa.eu/en/medicines/human/EPAR/vocabria\u003c/span\u003e\u003cspan address=\"https://www.ema.europa.eu/en/medicines/human/EPAR/vocabria\" targettype=\"URL\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eD'Amico R, Margolis DA. Long-acting injectable therapy: an emerging paradigm for the treatment of HIV infection. Curr Opin HIV AIDS. 2020;15(1):13\u0026ndash;8. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1097/coh.0000000000000606\u003c/span\u003e\u003cspan address=\"10.1097/coh.0000000000000606\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e. Epub 2019/11/26.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eDHHS Guidelines for the use of antiretroviral agents in adults and adolescents with HIV, Sept. 2022. Available at: \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/adult-adolescent-arv/guidelines-adult-adolescent-arv.pdf\u003c/span\u003e\u003cspan address=\"https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/adult-adolescent-arv/guidelines-adult-adolescent-arv.pdf\" targettype=\"URL\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (accessed December 2022).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eGESIDA Guidelines National Plan on AIDS regarding the antiretroviral treatment in adults infected with HIV. Jan 2022. Available at: \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://gesida-seimc.org/wp-content/uploads/2022/03/plan_nacional_gesida_tratamiento_antirretroviral.pdf\u003c/span\u003e\u003cspan address=\"https://gesida-seimc.org/wp-content/uploads/2022/03/plan_nacional_gesida_tratamiento_antirretroviral.pdf\" targettype=\"URL\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (accessed December 2022).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eThoueille P, Choong E, Cavassini M, Buclin T, Decosterd LA. Long-acting antiretrovirals: a new era for the management and prevention of HIV infection. J Antimicrob Chemother. 2022;77(2):290\u0026ndash;302. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1093/jac/dkab324\u003c/span\u003e\u003cspan address=\"10.1093/jac/dkab324\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e. Epub 2021/09/10.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eClinicalTrials.gov. Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants (FLAIR) \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://clinicaltrials.gov/ct2/show/NCT02938520\u003c/span\u003e\u003cspan address=\"https://clinicaltrials.gov/ct2/show/NCT02938520\" targettype=\"URL\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eClinicalTrials.gov. Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected Adults (ATLAS) \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://clinicaltrials.gov/ct2/show/NCT02951052?term=NCT02951052\u003c/span\u003e\u003cspan address=\"https://clinicaltrials.gov/ct2/show/NCT02951052?term=NCT02951052\" targettype=\"URL\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u0026amp;draw=2\u0026amp;rank=1.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eClinicalTrials.gov. Efficacy, Safety and Tolerability Study of Long-acting Cabotegravir Plus Long-acting Rilpivirine (CAB LA\u0026thinsp;+\u0026thinsp;RPV LA) in Human-immunodeficiency Virus-1 (HIV-1) Infected Adults (ATLAS-2M) \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://www.clinicaltrials.gov/ct2/show/NCT03299049\u003c/span\u003e\u003cspan address=\"https://www.clinicaltrials.gov/ct2/show/NCT03299049\" targettype=\"URL\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eOverton ET, Richmond G, Rizzardini G, Jaeger H, Orrell C, Nagimova F, et al. Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study. Lancet. 2021;396(10267):1994\u0026ndash;2005. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/s0140-6736(20)32666-0\u003c/span\u003e\u003cspan address=\"10.1016/s0140-6736(20)32666-0\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e. Epub 2020/12/15.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMurray M, Antela A, Mills A, et al. Patient-reported outcomes in ATLAS and FLAIR participants on long-acting regimens of cabotegravir and ilpivirina over 48 weeks. AIDS Behav. 2020;24:3533\u0026ndash;44.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBhattacharya R, Herren K, Poonawalla I, Bunniran S, Bloomfield A, Schwab P. Comparing Medical Utilization and Cost Outcomes in Oral Versus Injectable Immunotherapy Users with Chronic Inflammatory Joint and Skin Diseases. J Manag Care Spec Pharm. 2020;26(10):1246\u0026ndash;56. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.18553/jmcp.2020.26.10.1246\u003c/span\u003e\u003cspan address=\"10.18553/jmcp.2020.26.10.1246\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e. Epub 2020/10/01.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eVidal-Alaball J, Butler CC, Potter CC. Comparing costs of intramuscular and oral vitamin B12 administration in primary care: a cost-minimization analysis. Eur J Gen Pract. 2006;12(4):169\u0026ndash;73. Epub 2006/11/28. doi: 10.1080/14017430601049449. PubMed PMID: 17127603.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eOfford S, Wong B, Mirski D, Baker RA, Lin J. Healthcare resource usage of schizophrenia patients initiating long-acting injectable antipsychotics vs oral. J Med Econ. 2013;16(2):231\u0026ndash;9. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.3111/13696998.2012.751025\u003c/span\u003e\u003cspan address=\"10.3111/13696998.2012.751025\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eInstituto Nacional de Estad\u0026iacute;stica (INE). Indice de precios de consumo (IPC). Medias anuales. Consultado: junio 2022.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eRamgopal et al. CROI 2023; Virtual and Seattle, WA. Oral presentation 191.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eGutner C et al. Cabotegravir And Rilpivirine Implementation Study in European Locations (CARISEL): examining healthcare staff attitudes during a hybrid III implementation-effectiveness trial implmenting cabotegravir\u0026thinsp;+\u0026thinsp;rilpivirine long-acting injectable (CAB\u0026thinsp;+\u0026thinsp;RPV LA) for people living with HIV. Poster presented at: 18th European AIDS Conference; October 27\u0026ndash;30, 2021, virtual and London, United Kingdom. Poster PE2/56.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eGutner C et al. Healthcare staff perspectives on the implementation of HIV injectable treatment: interim results from the Cabotegravir And Rilpivirine Implementation Study in European Locations (CARISEL). Poster presented at: 18th European AIDS Conference; October 27\u0026ndash;30, 2021, virtual and London, United Kingdom. Poster PE2/36.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eHocqueloux L et al. Perspectives on the acceptability, appropiateness, feasibility, barriers, and facilitators from patients receiving cabotegravir\u0026thinsp;+\u0026thinsp;rilpivirine long-acting injectable treatment (CAB\u0026thinsp;+\u0026thinsp;RPV LA): interim results from the Cabotegravir And Rilpivirine Implementation Study in European Locations (CARISEL). Poster presented at: 18th European AIDS Conference; October 27\u0026ndash;30, 2021, virtual and London, United Kingdom.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eCalleja-Hern\u0026aacute;ndez MA, Mart\u0026iacute;nez-Sesmero JM, Vallejo-Aparicio LA, Hern\u0026aacute;ndez-Novoa B, Badia X. en representaci\u0026oacute;n del Grupo de estudio CAB\u0026thinsp;+\u0026thinsp;RPV AP MCDA. Contribuci\u0026oacute;n de cabotegravir\u0026thinsp;+\u0026thinsp;rilpivirina de acci\u0026oacute;n prolongada al tratamiento de la infecci\u0026oacute;n por VIH-1. Farm Hosp. 2022;46(4):208\u0026ndash;14.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMinisterio de Sanidad. Centros, servicios y establecimientos sanitarios. Centros y Servicios del Sistema Nacional de Salud. Accessed: 01/09/2022.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eServicio de Salud. (2017). Resoluci\u0026oacute;n de 15 de noviembre de 2017. Diario Oficial de Castilla-La Mancha n\u0026uacute;m. 226, 22 de noviembre de 2017.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eOsakidetza-Servicio Vasco de Salud. (2021). Acuerdo de 13 de diciembre de 2021. Bolet\u0026iacute;n Oficial del Pa\u0026iacute;s Vasco, n\u0026uacute;mero 3, 5 de enero de 2022.\u003c/span\u003e\u003c/li\u003e\u003c/ol\u003e"}],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":true,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":false,"hideJournal":false,"highlight":"","institution":"","isAcceptedByJournal":true,"isAuthorSuppliedPdf":false,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":false,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"bmc-infectious-diseases","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":false,"externalIdentity":"infd","sideBox":"Learn more about [BMC Infectious Diseases](http://bmcinfectdis.biomedcentral.com/)","snPcode":"","submissionUrl":"https://www.editorialmanager.com/infd","title":"BMC Infectious Diseases","twitterHandle":"#bmcinfectdis","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"em","reportingPortfolio":"BMC Series","inReviewEnabled":true,"inReviewRevisionsEnabled":true},"keywords":"Antiretroviral agents, cabotegravir, Costs and Cost Analysis, healthcare resource use, HIV, long-acting injectable, rilpivirine","lastPublishedDoi":"10.21203/rs.3.rs-3872460/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-3872460/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003ch2\u003eIntroduction:\u003c/h2\u003e \u003cp\u003eHIV treatment currently consists of daily oral antiretroviral therapy (ART). Cabotegravir\u0026thinsp;+\u0026thinsp;rilpivirine long-acting (CAB\u0026thinsp;+\u0026thinsp;RPV LA) is the first ART available in Spain administered every 2 months through intramuscular injection by a healthcare professional (HCP). The objective of this analysis was to assess potential healthcare resource use (HRU) and cost impact of implementing CAB\u0026thinsp;+\u0026thinsp;RPV LA vs. daily oral ART at National Health System (NHS) hospitals.\u003c/p\u003e\u003ch2\u003eMethods\u003c/h2\u003e \u003cp\u003eOnline quantitative interviews and cost analysis were performed. Infectious disease specialists (IDS), hospital pharmacists (HP) and nurses were asked about their perception of potential differences in HRU between CAB\u0026thinsp;+\u0026thinsp;RPV LA vs. daily oral ART, among other concepts of interest. Spanish official tariffs were applied as unit costs to the HRU estimates (\u0026euro;2,022).\u003c/p\u003e\u003ch2\u003eResults\u003c/h2\u003e \u003cp\u003e120 responders (n\u0026thinsp;=\u0026thinsp;40 IDS, n\u0026thinsp;=\u0026thinsp;40 HP, n\u0026thinsp;=\u0026thinsp;40 nurses) estimated an average number of annual visits per patient by speciality (IDS, HP, and nurse, respectively) of 3.3 vs. 3.7; 4.4 vs. 6.2; 6.1 vs. 3.9, for CAB\u0026thinsp;+\u0026thinsp;RPV LA vs. daily oral ART, and 3.0 vs. 3.2; 4.8 vs. 5.8; 6.9 vs. 4.9, respectively when adjusting by corresponding specialist responses. Estimation by the total sample led to an annual total cost per patient of \u0026euro;2,076 vs. \u0026euro;2,473, being \u0026euro;2,032 vs. \u0026euro;2,237 after adjusting by corresponding HCP, for CAB\u0026thinsp;+\u0026thinsp;RPV LA vs. daily oral ART.\u003c/p\u003e\u003ch2\u003eConclusions\u003c/h2\u003e \u003cp\u003eThese results suggest that the implementation of CAB\u0026thinsp;+\u0026thinsp;RPV LA in NHS hospitals would not incur in increased HRU-related costs compared to current daily oral ARTs, being potentially neutral or even cost-saving.\u003c/p\u003e","manuscriptTitle":"Potential healthcare resource use and associated costs of every 2 month injectable cabotegravir plus rilpivirine long-acting regimen implementation in the Spanish National Healthcare System compared to daily oral HIV treatments","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2024-03-14 19:45:09","doi":"10.21203/rs.3.rs-3872460/v1","editorialEvents":[{"type":"communityComments","content":0},{"type":"decision","content":"Revision requested","date":"2024-05-17T08:10:41+00:00","index":"","fulltext":""},{"type":"editorInvitedReview","content":"","date":"2024-05-15T23:04:57+00:00","index":"hide","fulltext":""},{"type":"reviewerAgreed","content":"733e8257-a986-4319-ac6f-1e819534ddfc","date":"2024-04-26T11:33:03+00:00","index":"hide","fulltext":""},{"type":"editorInvitedReview","content":"","date":"2024-04-18T15:45:04+00:00","index":"hide","fulltext":""},{"type":"editorInvitedReview","content":"","date":"2024-04-01T08:32:38+00:00","index":"hide","fulltext":""},{"type":"reviewerAgreed","content":"23ee0d76-8d15-478b-9700-03e009ecb7d4","date":"2024-03-31T08:06:10+00:00","index":"hide","fulltext":""},{"type":"reviewerAgreed","content":"bce80475-03ae-484d-8eeb-de5d7767d54e","date":"2024-03-30T09:02:18+00:00","index":"hide","fulltext":""},{"type":"reviewersInvited","content":"","date":"2024-03-30T09:00:52+00:00","index":"","fulltext":""},{"type":"editorAssigned","content":"","date":"2024-03-27T05:18:15+00:00","index":"","fulltext":""},{"type":"editorInvited","content":"","date":"2024-03-12T17:22:32+00:00","index":"","fulltext":""},{"type":"checksComplete","content":"","date":"2024-03-12T14:44:31+00:00","index":"","fulltext":""},{"type":"submitted","content":"BMC Infectious Diseases","date":"2024-01-17T09:26:29+00:00","index":"","fulltext":""}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"bmc-infectious-diseases","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":false,"externalIdentity":"infd","sideBox":"Learn more about [BMC Infectious Diseases](http://bmcinfectdis.biomedcentral.com/)","snPcode":"","submissionUrl":"https://www.editorialmanager.com/infd","title":"BMC Infectious Diseases","twitterHandle":"#bmcinfectdis","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"em","reportingPortfolio":"BMC Series","inReviewEnabled":true,"inReviewRevisionsEnabled":true}}],"origin":"","ownerIdentity":"010f7ac8-ad82-41d8-84f9-593865f1ae32","owner":[],"postedDate":"March 14th, 2024","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"published-in-journal","subjectAreas":[],"tags":[],"updatedAt":"2024-08-05T16:03:05+00:00","versionOfRecord":{"articleIdentity":"rs-3872460","link":"https://doi.org/10.1186/s12879-024-09595-4","journal":{"identity":"bmc-infectious-diseases","isVorOnly":false,"title":"BMC Infectious Diseases"},"publishedOn":"2024-08-02 15:57:36","publishedOnDateReadable":"August 2nd, 2024"},"versionCreatedAt":"2024-03-14 19:45:09","video":"","vorDoi":"10.1186/s12879-024-09595-4","vorDoiUrl":"https://doi.org/10.1186/s12879-024-09595-4","workflowStages":[]},"version":"v1","identity":"rs-3872460","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-3872460","identity":"rs-3872460","version":["v1"]},"buildId":"qtupq5eGEP_6zYnWcrvyt","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}